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INTRODUCTION
1INTRODUCTION
Hypertensive disorders during pregnancy continue to be a major
cause of maternal and perinatal morbidity and mortality worldwide. In
developing countries they are second only to anemia with approximately
3- 10 %of all pregnancies.
Pritchard et al observed “in order to effect a complete cure from
preeclampsia the chorionic villi must be expelled or surgically removed
.Rodger  et  al  and  Music  et  al  postulated  that  the  endothelial  cells  are
affected by a cytotoxic  factor produced by the trophoblastic cells which
is responsible for the pathophysiology of preeclampsia1.
One such theory states that “the decidua and amniotic fluid
contains a toxin called HYSTEROTONIN which acts as a pressor
substance leading to the development of preeclampsia. It is found in
women with preeclampsia.  Resolution of preeclampsia and eclampsia
occurs by delivery and complete removal of trophoblastic cells.
Preeclampsia resolves only after all gestational products
particularly the placenta and decidua have been removed or have ceased
to function. Therefore removal is the best means of cure of the disease.
2We consider the above theory and therefore by immediate postpartum
curettage we try to remove all the decidual tissues therefore hastening the
recovery. Hence in patients with severe preeclampsia accelerated
recovery following delivery will minimize serious and life threatening
maternal complications thereby minimizing the patients stay in intensive
care and prolonged hospitalisation.
This  thesis  is  done  to  study  the  effect  of  immediate  postpartum
curettage on the resolution of clinical and laboratory indices associated
with severe preeclampsia.
REVIEW OF LITERATURE
3REVIEW OF LITERATURE
PREECLAMPSIA
Preeclampsia is a pregnancy-specific disorder defined clinically as
hypertension and proteinuria occurring after 20 weeks gestation.
Preeclampsia is a common complication occurring in the second trimester
and is potentially dangerous to both mother and fetus.  Preeclampsia
occurs in 3-10% of pregnancies and approximately 50 000 women
worldwide die from this disease every year2.
The pathogenesis of preeclampsia is not fully understood.
Considerable research over more than five decades has led to the notion
of preeclampsia as a multifactorial syndrome with maternal and fetal
interaction.
DEFINITIONS
According to the National High Blood Pressure Education Program
Working Group on High Blood Pressure in Pregnancy3, the following
classifications are recommended.
4Preeclampsia:
A syndrome defined by hypertension and proteinuria after 20
weeks of gestation. Hypertension is defined as a systolic blood pressure
level of 140mm/Hg or higher or a diastolic blood pressure level of 90 mm
/Hg or higher occurring after 20 weeks gestation in a woman with
previously normal blood pressure. Proteinuria is defined as urinary
excretion of 0.3 gram of protein or higher in a 24-hour urine specimen (or
protein dipstick reading equal to or higher than 1+ on more than one
midstream urine sample six hours apart).
Eclampsia:
The occurrence of seizures in a preeclamptic woman, where the
seizures cannot be attributed to other causes.
Gestational hypertension:
Blood pressure elevation without proteinuria developing in a
woman after 20 weeks’ gestation, with blood pressure levels returning to
normal postpartum.
5Chronic hypertension:
Hypertension that is observable before pregnancy or before
20weeks’ gestation. Hypertension that is primarily diagnosed during
pregnancy and which persists beyond the 42nd day postpartum is also
classified as chronic hypertension.
Superimposed preeclampsia:
Preeclampsia developing in a patient with chronic hypertension.
PATHOGENESIS
PREECLAMPSIA AND DEFECTIVE PLACENTATION
      The complex molecular inheritance between the mature blastocyst
and the uterine endometrium which is primed hormonally is the final
result of a successful implantation4. The function of the uteroplacental
unit is to secure an adequate exchange of nutrients, gases and metabolic
end products. These functions are mediated by increased blood flow
through the uterus. During the early phase of placental development,
extravillous cytotrophoblasts (stemming from the outer cell-layer of the
blastocyst) stream out of the anchoring villi, penetrating the
syncytiotrophoblast layer, entering the decidua and invading and
6transforming the maternal spiral arteries. The major structural alterations
occurring in these spiral arteries in early pregnancy (so-called
“physiological changes”) normally transform the arteries to vascular
channels outside maternal vascular control, allowing an increased
maternal blood supply to the placenta 5 in  the last  part  of  the pregnancy
(figure I).
Trophoblast invasion of the decidua and maternal myometrium is
thought to be a key event in early placentation6. Reduced trophoblast
invasion may represent one of the basic defects leading to
preeclampsia7.This reduced invasion of extracellular trophoblast is
followed by a shallow transformation of the spiral arteries 6, leaving them
narrow, tortuous and thickwalled. Besides remaining non-transformed,
the spiral arteries in preeclampsia can have areas of lipid deposition in the
vessel wall, a phenomenon known as acute atherosis. The name was
given  to  the  changes,  first  observed  in  1945,  as  a  result  of  the
morphological resemblance of early phases of atherosclerotic lesions in
vessels8. There is still some controversy and insufficient knowledge
regarding the etiology and molecular mechanisms behind the formation
of acute atherosis. This is partly due to the difficulty in obtaining
7sufficient and adequate tissue from the placental bed, as well as a lack of
relevant animal models.
Normal placental function relies on adequate maternal blood
supply through the wholly or partially transformed spiral arteries in the
placental bed (figure I). Any process that results in mural or occluding
thrombi in these arteries reduces the flow and can lead to hypoxia and
ischemia as well as infarcts in the placental tissue, i.e. reduced placental
function, which is more common in preeclampsia than in uncomplicated
pregnancies 9.
Term Placental Structure
The arrows represent blood flow from the decidual arteries into the
intervillous spaces and back into the venous blood (modified after
Junqueira LC et al.Basic Histology. Appleton and Lange 1989: 452-458)
8Oxidative stress and maternal endothelial dysfunction is due to the
toxic compounds released by the hypoxic placenta into the maternal
circulation10,11. Acute atherosis in spiral arteries is associated with an
increased risk of thrombosis and thereby placental ischemia and
infarctions 9.Bearing in mind the multifactorial aspects of preeclampsia,
defect in  placentation additionally seems to be related to immunological
processes such as decreased trophoblast expression of human leucocyte
antigen-G (HLA-G) 12, as well as interaction with maternal lymphocytes
such as uterine natural killer (NK) cells 13
INFLAMMATION AND ENDOTHELIAL DYSFUNCTION
Endothelial cells represent a semipermeable barrier between the
vessel wall and the blood flow in the vascular system 14. Hemostasis is
mainly regulated by the endothelial lining of the cells via a series of
receptors for proteins, hormones, lipid transports as well as through cell-
cell interactions 15.
“Endothelial dysfunction” has not been precisely defined, but the
term is used to indicate change in endothelial properties with activation
and abnormal function 16. Evidence suggests that endothelial activation
and low grade maternal inflammation is present in all pregnancies, there
9being merely a different gradient in preeclampsia, with a stronger
inflammatory response 17. The central pathological features of the
maternal syndrome may thus include the presence of an excessive
maternal inflammatory response, resulting in dysfunction, activation and
peripheral vasoconstriction with reduced circulating volume, which in
turn leads to oxidative stress 17.
PREECLAMPSIA AND THE TWO-STAGE-MODEL
The present concept of the pathogenesis of preeclampsia involves a
two-stage model. Stage 1 refers to a defect and reduced trophoblast
invasion into the maternal spiral arteries (with reduced physiological
arterial changes or remodeling) leading to reduced placental perfusion.
Stage 2 refers to a generalized dysfunction and activation of the
endothelium and finally development of the maternal syndrome18,19.
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Several factors have been proposed as the link between the two
stages of preeclampsia such as the angiogenic factors20-22, oxidized
lipids23 and syncytiotrophoblastic debris24 which  are  released  by  the
placenta into the maternal circulation. Recent theories state that the
angiogenic associated factors like sFlt (soluble fms like tyrosine) and
endoglin released from a hypoxic placenta are responsible for the
endothelial damage25.
Oxidative stress in preeclampsia
The biochemical imbalance between antioxidant protection and
free radical damage is defined as oxidative stress26. It arises from
excessive generation of free radicals and inadequate endogenous
antioxidant capacity 27,28. Reactive oxygen species (ROS) are constantly
11
produced as by-products of normal oxidative metabolism in mitochondria
and other cellular reactions 29,30.  All  organisms  possess  a  range  of
enzymatic and non enzymatic antioxidant systems, which serve to protect
against the harmful oxidative reactions that occur as a consequence of
this endogenous ROS production. Some of the enzymatic antioxidents are
glutathione reductase, superoxide dismutase and catalase. Some of the
non enzymatic antioxidents are vitamins A,C& E , flavonoids and
glutathione.31Under certain conditions, an increase in oxidants and a
decrease in antioxidants cannot be prevented, and the oxidant/ antioxidant
balance shifts towards the oxidative state. This  oxidative stress is
responsible for the pathological changes and endothelial dysfunction in
preeclampsia 32-34.
Pregnancy itself is a condition of increased oxidative stress 35, and
may contribute to endothelial dysfunction and the clinical development of
preeclampsia 36,37. There is considerable evidence supporting an increase
in products of oxidative stress in women with preeclampsia, demonstrated
both in the placenta 21,38 and in maternal peripheral blood cells 33, as well
as in the maternal circulation 39. There is still some controversy with
respect to the results for latter compartment 40,41.
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A number of circulating compounds may under certain
circumstances enhance oxidative stress. They include lipoproteins, lipids,
proteins, glucose and advanced glycation end products (AGEs).An
established method for measuring the end products of increased oxidative
stress is to measure the degree of lipid peroxidation. Lipid peroxidation
occurs when ROS interact with polyunsaturated fatty acids in membranes
or lipoproteins 42. In preeclampsia, there is development of excessive
maternal hyperlipidemia, and especially hypertriglyceridemia, as
compared to normal pregnancy 43,44 and these changes are present long
before the onset of preeclampsia 45. Oxidation of low density lipoproteins,
which are prominent in preeclampsia, is one example of the measurable
consequences of increased oxidative stress46.
There are several methods of examining lipid peroxidation
products in biological samples, but most of them have both low
specificity and low sensitivity in terms of measuring changes in free
radical status. Among such lipid peroxidation products are
the19tiobarbituric acid reactive substances (TBARS), lipid
hydroperoxides and the isoprostanes47-49.There  are  also  end  products  of
oxidative stress, other than lipid peroxidation products, that can be
measured as indices of oxidative stress. Direct damage to proteins by
peroxidation of the amino acids can also give rise to protein carbonyls,
13
which may serve as more general biomarkers of oxidative stress 50.
Plasma protein carbonyls have been demonstrated to be elevated in
preeclampsia as compared to controls 51.Peroxinitrate, produced by the
vasorelaxant nitric oxide (NO) reacting with superoxide anions (produced
under conditions of oxidative stress) is also a potential marker of
oxidative stress. Peroxinitrite is regarded as a marker of  “nitrative stress”
which, subsequent to oxidative stress, is seen in the placenta in
preeclampsia and diabetes in association with altered placental function
52.  NO is  produced  by  endothelial  cells  and  is  also  known to  react  with
superoxide anions (produced under conditions of oxidative
stress),yielding peroxynitrite that may impair vascular function53.
ANGIOGENIC FACTORS IN PREECLAMPSIA
Considerable attention has recently been focused on angiogenesis-
related factors in the etiology of preeclampsia. It has been postulated that
preeclampsia might be a syndrome of angiogenic disorders and that the
angiogenic factor like  soluble fms-like tyrosine kinase 1(sFlt1) plays a
role in the pathophysiology of preeclampsia25,54. Growth factors like PlGF
(placental growth factor) and VEGF (vascular endothelial growth factor)
are necessary for the endothelial function and the angiogenesis and
vasculogenesis  of early placentation55.
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Recently the anti-angiogenic factor sFlt1, which binds soluble
VEGF and PlGF and inhibits their effect on the vascular endothelium,
was found to be up-regulated in preeclamptic placentas25. High serum
levels of sFlt have been found in preeclampsia24,25, and increased sFlt
1concentrations  in the serum predict the onset of preeclampsia in the
second trimester 23. A recent Norwegian study also showed that a low rise
of maternal PlGF and a high rise of sFlt1 between the first and second
trimester are strong predictors of early onset preeclampsia 26.
Summary of the pathogenesis of preeclampsia? Immune factors
(such as AT1-AA), oxidative stress, NK cell abnormalities, and other
factors may cause placental dysfunction, which in turn leads to the
release of anti-angiogenic factors (such as sFlt1 and sEng) and other
inflammatory mediators to induce hypertension, proteinuria, and other
complications of preeclampsia.
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Recently, soluble endoglin (sEng) has been found in elevated
concentrations in preeclamptic maternal serum26 sEng  and  sFlt1  causes
endothelial dysfunction in vitro by blocking the angiogenic effects of
TGF-  and  VEGF  and  can  also  induce  an  illness  similar  to  severe
preeclampsia in pregnant rats25,26.
PATHOGENESIS OF PREECLAMPSIA
Preeclampsia has been rightly termed as the disease of theories and
the various pathogenic mechanism involved are  as follows
1. Abnormal trophoblastic invasion
2. Inflammation and endotheial cell injury
3. Oxygen disruption
4. Antiangiogenic factors
16
RISK FACTORS
One  out  of  every  three  woman  who  are  preeclamptic  has  a
significant risk factor. As per NICE(NATIONAL INSTITUTE OF
CLINICAL EXCELLENCE) guidelines, a carefull and detailed history
taking should be done at every woman’s first antenatal visit in order to
ascess her risk level for developing  preeclampsia and her subsequent
antenatal visits can be planned from the evaluation made.
RISK FACTORS –NICE guidelines
1. Nulliparity
2. History of preeclampsia in a first degree relative like sister/mother
3. Age >40 years
4. Previous obstetric history of preeclampsia
5. BMI(body mass index) >35 in the first visit
6. Preexisting vascular diseases like diabetes and hypertension56.
7. Multiple pregnancy
Recently some of these risk factors have been quantified at the
booking visit by a systemic review57 .
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History of preeclampsia in the family signifies the genetic
influence of the disease. Preeclampsia is more frequently seen in
primigravida patients58. The development of preeclampsia in the fetus
exposed to the affected paternal antigen suggest a significant
immunological influence of the disease .Similarly  if this pregnancy is
conceived with a partner who had already fathered a preeclamptic
pregnancy then the risk of preeclampsia is doubled in this pregnancy61.
Increased duration of sexual cohabitation and the use of contraceptives of
non-barrier methods are known to decrease the risk of preeclampsia59,60.
If the patients has any associated medical illness involving the
CVS or any form of carbohydrate intolerance such as gestational diabetes
mellitus or pre-gestational diabetes the risk of preeclampsia is increased
in the mother62,63. One of the important independent risk factor of
preeclampsia is obesity.
Size of the placenta also appears to be an independent risk factor as
can be seen in molar pregnancies which are rare causes of early onset
preeclampsia. Patients with complicated pregnancies like trisomy
chromosomal anomaly in the fetus or the presence of hydrops fetalis also
called as mirror syndrome are also known to have an increased risk of
preeclampsia. Every one out of five patients who had a  previous history
18
of preeclampsia associated with delivery of the fetus before 37 weeks due
to preeclampsia are known to have a recurrence of preeclampsia in the
present pregnancy as well.
INVESTIGATIONS
Predictive tests for preeclampsia is divided into biophysical and
biochemical test
Biophysical Tests
1. Uterine artery Doppler
2. Blood pressure measurement in early pregnancy
3. Isometric exercise testing
4. Roll over test
5. Angiotensin II sensitivity test
Biochemical and Haematological Test
1. Haemoglobin and PCV
2. Serum uric acid
3. Platelet count
4. Beta HCG and alpha fetoprotein
5. sEng(soluble endoglin ) and sFlt 1
6. urinary calcium excreation
7. prostacyclin metabolites
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Uterine Artery Doppler
It is a quick and relatively inexpensive test that is usually done
around 20 weeks of gestation .ie. around the time anomaly scan is being
performed to identify poor placental perfusion ,the main reason for the
pathophysiology of the disease process64.The uterine artery Doppler
shows a high resistant circulation with a diastolic notch which is an
important predictator of preeclampsia. But due to a delay in the change to
a low resistant circulation even in some normal pregnancies the positive
predictive value of the test can be improved by performing the test at a
later gestational age especially around 24 week which increases the
predictive value of the test.
One in every five woman with an abnormal high resistant
circulation with a diastolic notch in the uterine artery Doppler performed
at around 20 weeks of gestation have an increased risk of developing
preeclampsia. Thus Doppler helped to identify high risk woman at an
earlier gestational age there by allowing the use of prophylactic therapies
to decrease the severity of the disease. However the use of this
biophysical test for improving the outcome of the disease process has not
yet  been  established  and  as  clearly  stated  by  NICE  who  do  not
recommend the use of Doppler in low risk woman.
20
Normal “low resistance” uterine artery waveform in the midtrimester.
Abnormal uterine artery vascular resistance, showing increased pulsatility
and the presence of an early diastolic notch.
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Blood Pressure Measurement In Early Pregnancy
Alteration in the circadian variability are present as early as first
trimester in a women at risk of preeclampsia. But due to its subjective and
objective variability it is an inaccurate predictor of pre eclampsia65.
Others like Isometric exercise testing and Roll over test have low
predictive value.
Angiotensin Ii Sensitivity Test
A women at risk of developing preeclampsia will respond to less
than 8 ng/kg  min of angiotensin infusion due to alteration of vessel wall
refratoriness. This test is done between 26 – 30 weeks66.
Biochemical And Hematological Predictors Of Pre Eclampsia
Hemoglobin and hematocrit are poor predictors of preeclampsia as
does plasma volume. In chronic hypertension patients serum uric acid and
platelets can be measured to identify those patients with a superimposed
pre eclampsia but they lack sensitivity and specificity. Beta HCG and
alpha fetoprotein measured in the second trimester increases the risk of
preeclampsia two fold. This is due to the pathological process taking
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place at the utero- placental interface. But the positive predictive value
for beta HCG and alpha fetoprotein is very low and hence not clinically
practicable.
Endothelial markers such as soluble fms like tyrosine kinase 1,
placental growth factor, vascular endothelial growth factor and soluble
endolglin are also predictors of preeclampsia. These act by inhibiting the
nitric oxide action of vasodilatation. However these are also seen in
normal women thereby limiting the clinical usefulness of these markers.
Urinary Kallikrein / creatinine ratio of < 170 between 16 and 20
weeks  having  sensitivity  of  70  %  and  specificity  of  86  %   predicts  the
future development of preeclampsia.
Urinary calcium excretion is reduced in preeclampsia due to
increased proximal and distal tubular calcium re-absorption. A urinary
calcium level   of<12mg/dl has sensitivity of 91 %.Antithrombin III is
reduced in preeclampsia which correlates with maternal and perinatal
outcome.
Serum fibronectin levels are elevated in preeclampsia. In
preeclampsia Pregnancy associated plasma protein A(PAPP-A) is
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reduced in first trimester. Both these markers are associated with two fold
risk of developing preeclampsia later in pregnancy.
PREVENTION OF PREECLAMPSIA
Numerous interventions have been tried to reduce the severity of
preeclampsia.
Diet and exercise
Various studies investigating the role of protein restriction or
supplementation, aerobic exercises, magnesium and zinc
supplementation, and decreased salt intake have given conflicting results.
But randomized controlled studies have reported minimal or no benefit67.
Calcium supplementation
A systematic review has found 30 % reduction in the risk of
preeclampsia with an intake of 1 gram calcium per day68. This effect is
greatest for women at high risk of developing preeclampsia and for those
with  previous  low  calcium  intake.  But  this  reduction  did  not  have  an
effect on still birth and neo natal mortality rate.
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Aspirin and ant-platelet agents
CLASP (Collobarative low dose aspirin study), a large
randominised control study reported a reduction of preeclampsia in 12%
but this was insignificant. However some benefit was seen in a small
subset of women who were at high risk of developing preeclampsia when
aspirin was started early in the pregnancy. Also it showed that low dose
aspirin  was  safe  for  the  fetus.  By  comparing  the  results  of  43  trials
antiplatelet agents and low dose aspirin were found to decrease the risk of
preeclampsia by 19%.  Similarly an 8% reduction in preterm births and a
14% reduction in perinatal mortality were seen in patients on a
prophylactic dose of aspirin69,70.
Use of fish oils with N3 fatty acid which inhibit platelet
thromboxaneA2 did not show a significant reduction in preeclampsia.
Since  oxidative  stress  is  an  important  factor  to  the  development  of  the
disease process vitamin C and E supplementation in the dosage of
1000mg and vitamin D 400 IU, in the second half of pregnancy
demonstrates more than a 50%  reduction in the risk of preeclampsia71
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CLINICAL FEATURES
The classic triad of preeclampsia are
? Hypertension, defined by Systolic pressure > 140mm of Hg
and Diastolic > 90mm of Hg.
? Proteinuria - 0.3 g in a 24-h urine specimen or protein to
creatinine ratio of >0.30.
? Edema, though non-specific, sudden onset of gross edema of
the hands and face, is a definitive feature in the diagnosis of
preeclampsia.
The clinical presentation of preeclampsia varies widely,even
without the presence of all three classical symptoms. It has been reported
that 10% of cases of gestational hypertension without significant
proteinuria have progressed to severe preeclampsia72. Hence a strict
follow-up of patients with isolated hypertension is necessary and
lifesaving in the antenatal period73,74.
Another study by Lafayette et al ., has showed significant reduction
in  the  GFR  in  preeclampsia  patients  while  the  renal  plasma  flow  and
oncotic pressure remains normal75.
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Some of the serious complications include pulmonary edema,
seizures, acute kidney injury, abruption placentae and in extreme cases,
HELLP syndrome has been reported. The triad - Hemolysis, Elevated
Liver enzymes76 and Low Platelets is associated with serious maternal
and neonatal complications.
The pathogenesis of preeclampsia- subtle vascular damage and
persistent endothelial dysfunction is the reason for a variety of related
complications. In the long term about 20% of preeclampsia patients
develop either hypertension or microalbuminuria within 7 years of the
last pregnancy. Other serious long term complications include Renal - an
increased risk of End Stage Renal Disease (ESRD), Cardiovascular –
increased TGL, LDL, Sr.Cholesterol and BMI values and cerebrovascular
diseases.
PREECLAMPSIA AND FETAL ASPECTS
The fetal well-being and development in utero during  pregnancy is
dependent on  both the fetal genes and the intrauterine environment. The
intrauterine environment is mainly mediated through the placenta, which
serves all the needs of the infant, including nutritional and oxygen supply,
disposing of waste products as well as serving hormonal support for fetal
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growth and development. In pregnancies complicated with preeclampsia,
the consequences for the fetus may be due to both prematurity, like lack
of lung maturation and growth restriction, as well as the long term
consequences for the infant, like increased risk of developing
cardiovascular disease, dying from stroke and developing hypertension in
adulthood77.
In preeclampsia the final common pathway is believed to be due to
maternal endothelial dysfunction10,11. This endothelial dysfunction is
believed to be due to the release of certain agents into the maternal
circulation by the hypoxic placenta.78-81. Prematurity has been associated
with increased oxidative stress82-84, and oxidative stress has also been
implicated in several of the diseases of prematurity such as
bronchopulmonary dysplasia, intraventricular hemorrhage and
necrotizing enterocolitis84-86. 8-isoprostane, an acknowledged marker of
oxidative stress, has been demonstrated to be elevated in plasma of
preterm infants compared to term infants in only one study 87,  and  also
low concentrations of antioxidants in the fetal circulation have been
demonstrated, possibly representing infants more vulnerable to oxidative
injury88-90. Since preeclampsia is associated with increased oxidative
stress both in the maternal circulation and in the placenta, it is of interest
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to explore whether this imbalance between pro-and antioxidants also is
present in the circulation of an infant born to a preeclamptic mother.
MANAGEMENT OF PREECLAMPSIA
It is concerned with the maximal prolongation of the duration of
pregnancy without affecting the maternal or fetal well being.
? Admission and rest
One study compared the effect of bed rest with that of liberal
ambulation on the physiological changes of preeclampsia. Renal
function had no improvement but the placental function had some
signs of improvement.
? BP monitoring91,92
? Urine albumin and urine output monitoring daily
? Fetal monitoring
? Watch for signs of imminent eclampsia
? Antihypertensive therapy
Oral labetalol is a beta blocker and is the drug of choice in
preeclampsia93.It is started when the BP persistently stays above
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150/100mm/Hg.It is started in dosage of 200mg BD upto a maximum
dose of 2.4 g. However it can reduce the cardiac output to the uterus
leading  to  IUGR.  Other  drugs  such  as  Nifedipine  ,a  calcium  channel
blocker can be given in dosage of 5-10mg BD. It acts by blocking the
calcium influx into the smooth muscle cells, interfering with the
excitation – contraction coupling of the muscle. Side effects include
headache, facial flushing and warm , sweaty extremities.
? Timing of delivery
About 50% of patients with mild preeclampsia will develop severe
preeclampsia  remote  from  term.  They  are  even  at  a  risk  of  developing
eclampsia   suddenly without warning and with minimal BP elevations.
Other such serious complication is abruption placenta. But both these
risks constitute <1%. In mild preeclampsia the use of antihypertensive
agents helps to reduce the progression to severe preeclampsia but offers
no benefit to the fetus.
Pregnancy is terminated at 38 weeks by inducing labour or by an
elective cesarean section if cephalopelvic disproportion is seen or much
earlier or if it progresses to severe preeclampsia.
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If the disease progresses from mild to severe or if there is an
indication of fetal compromise like oligohydramnious, non-reassuring
fetal heart rate pattern or intrauterine growth restriction the patient must
be planned for delivery.
Serial laboratory evaluation of platelet count, haemoglobin
,haematocrit, serum uric acid ,blood urea & creatinine , liver enzymes
like SGOT, SGPT, SAP, urine for albumin must be done weekly to
monitor for worsening of the disease. Also patients are instructed to
monitor daily fetal kick count and undergo twice weekly non stress test
and amniotic fluid index, weekly biophysical profile . Doppler and
ultrasound for fetal growth should be done once in every 3-4 weeks .
Once the diagnosis is established the only cure is termination of the
pregnancy. The indicators for termination of pregnancy are as follows
? Persistently elevated BP of 160/110 mm/Hg
? Proteinuria >5 grams in 24 hour
? Headache &blurring of vision
? Epigastric pain
? HELLP syndrome
? Compromised renal function test
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? Oliguria <400 ml in 24 hours
? Pulmonary edema
? Abruption placenta
? Eclampsia
? IUGR with abnormal Doppler
? Evidence of fetal distress like non reactive CTG, biophysical
profile of <4 on two occasions ,four hours apart, severe
IUGR <5 th percentile for gestational age and severe
oligohydramnious.
? Fetal death ,rupture of membrane, spontaneous labour
? Gestational age >34 weeks in cases of severe preeclampsia
MANAGEMENT OF SEVERE PREECLAMPSIA
Before 24 weeks of gestation termination of pregnancy is
recommended. The preferred mode is induction of labour if the BP levels
are well controlled without any toxic clinical appearance.
The management of severe preeclampsia in mid trimester ( 25 – 32
weeks)- Steroids were given to hasten lung maturity and delivery can be
delayed after 24 hours if possible. During this period extensive maternal
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and fetal surveillance should be done. While conservative management
may be associated with an increase in maternal complications, aggressive
management in delivery may result in neonatal mortality.
Expectant management in severe preeclampsia before 32 – 34
weeks in patients having only increased proteinuria > 5 gram in 24 hours
is  justified  to  prolong  the  gestation.  Patients  >  34  weeks  should  be
delivered. In these patients diastolic BP should be maintained between
95- 105 mm hg. It is always better to induce the labour provided there are
no contraindications such as severe IUGR or contracted pelvis. However
the threshold for cesarean section should be kept low. Large amount of
peritoneal fluid is found during cesarean.
Objectives in the management :
? To prevent complications such as pulmonary edema,renal failure,
abruption and cardiovascular complications .
? To prevent convulsions as it is associated with 10 times increased
risk of maternal and perinatal mortality.
? To deliver a healthy baby with least maternal morbidity.
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As volume contraction is poorly tolerated in these patients , it is
prudent to take necessary steps to minimize blood loss. Cross matched
blood and blood products should be kept ready. She should be assisted in
second  stage  of  labour  inorder  to  prevent  the  rise  in  BP  during  each
uterine contraction. Methyergometrine is contraindicated .
Appropriate steps should be taken to minimize postpartum
hemorrhage particularly in patients receiving MgSO4.
Antihypertensives in severe pre eclampsia
Intravenous hydralazine , intravenous labetalol and oral nifidepine
are the commonly used agents to control acute ,very high BP.
Hydralazine is given at a dosage of 5 – 10 mg intravenous every 20
minutes upto a maximum dosage of 30 mg. It may cause headache,
nausea , vomiting and maternal hypotension.
Labetalol is given at 10 – 20 mg iv , then 40 – 80 mg every 10
minutes upto a maximum dosage of 300 mg , a continuous infusion of 1-2
mg can also be used. It has a favourable side effect profile except for the
fetal bradycardia it causes
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 Sublingual nifedipine is not used due to fear of severe
hypotension. Oral nifedipine is given at a dosage of 10 mg , repeated
every 30 minutes, followed by 10 – 20 mg every 4 hours, upto a
maximum of 240mg. In conjunction with MgSO4 it may cause profound
hypotension and hence it should be carefully used in coronary heart
disease patients.
Intravenous sodium nitroprusside can be used in refractory
hypertension with fetal cyanide poisoning being the risk on prolonged
treatment. Usually hypertension resolves 24 hours after delivery. If it
persists antihypertensives are continued. A diagnosis of chronic
hypertension should be considered if hypertension persists for more than
6 weeks postpartum.
The HELLP Syndrome
Weinstein coined the acronym HELLP in 1982 to aid clinicians in
recognizing this group of patients with remarkable hepatic involvement
by severe preeclampsia (Weinstein 1982). Indeed the features of the
HELLP syndrome are very similar and sometimes difficult to distinguish
from those of other microangiopathic syndromes that may develop in late
pregnancy such as hemolytic uremic syndrome and thrombotic
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thrombocytopenic purpura.  The latter disorders are characterized by
vascular endothelial cell damage, elicited by unknown antigens or toxic
substances. Differentiation of these disorders from the HELLP syndrome
is important because the latter is treated by urgent delivery, whereas
hemolytic uremic syndrome or thrombotic thrombocytopenic purpura
may require plasma infusion or plasmapheresis.
Sibai has noted that most patients with the HELLP syndrome
present preterm with hypertension and proteinuria and report epigastric
and upper-right quadrant pain (1990).  Around 30%of HELLP cases
develop postpartum. The following criteria are used to establish the
diagnosis of the HELLP syndrome(Sibai 2002):
? Hemolysis
? Abnormal peripheral blood smear
? Increased bilirubin  ?1.2mg/dl
? Increased lactate dehydrogenase (LDH) >600 IU/I
? Elevated liver enzymes
? Increased SGOT ? 72 IU/I
? Increased LDH>600 IU/I
? Thrombocytopenias
? Platelet count < 1 00,000 cumm
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Most obstetricians consider the development of HELLP syndrome
as an indication for urgent delivery, because the laboratory values can
reach life threatening levels with severe thrombocytopenia and elevated
liver enzymes. Liver rupture is rare, with a high mortality rate requiring
large amounts blood and blood products transfusions and laparotomy,
drainage and packing.
The maternal condition is first assessed and stabilized. Blood
investigations are taken to assess the biochemical severity.
Antihypertensives are started. MgSO4 started as seizure prophylaxis94.
The fetal condition is also assessed and the decision to deliver
immediately is decided upon.
High dose corticosteroids (10 mg iv dexamethasone every 6 hours
for two doses, followed by 6 mg every 6 hours two doses)   are given to
improve maternal condition as steroids appear to alter the final steps of
endothelial cell disruption.
The HELLP syndrome is classified based on platelet count as
Class 1 –(< 50,000), Class 2 – (50,000 – 1 lakh) and Class 3 – (1 lakh-
1,50,000). They help to predict the rapidity of postpartum delivery.
Platelet transfusions are indicated, either before or after delivery, in the
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presence of significant bleeding from puncture sites and so on. It is
necessary to transfuse when platelet count is less than 20,000.
Thrombophilia and Preeclampsia
A combination of aspirin and heparin or low molecular weight
heparin is effective in recurrent fetal loss in the APLA syndrome and the
other inherited thrombophilias.
Seizure Prophylaxis
MgSO4 can be given in severe preeclamptic patients to prevent
convulsions95.
Anesthesia and analgesia
Continuous epidural analgesia is very useful for vaginal and
operative delivery96. It offers dual benefits of analgesia and stabilization
of BP. It prevents the release of catecholamines during uterine
contractions. It abolishes excessive bearing down during the second stage
labour. Patient should be adequately preloaded , fully conscious and
coagulopathy must be excluded before inserting the epidural catheter.
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If general anesthesia is indicated , the following risk should be kept
in mind.
1) Laryngeal edema which makes intubation difficult
2) The pressor response to intubation precipitating pulmonary edema
or arrhythmia.
3) Risk of aspiration
4) Decrease in uteroplacental flow which may hazardous to severe
IUGR fetus
5) Neuromuscular blockade
Postnatal assessment
Persistence of hypertension or proteinuria after 6 weeks
necessitates futher work up97. Pregnancy should be advised only if BP
and renal function tests return to normal. It is necessary to councel the
patients for early booking of future pregnancies. The advantageinclude
early administration of aspirin and detection of preeclampsia at the
earliest.
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RECURRENCE
The risk of recurrent preeclampsia was 3.4 %. The risk of recurrent
hypertension without proteinuria was even more higher  about 25%. Pre
eclampsia developing in second trimester during first pregnancy proposes
60 % risk of recurrence in second pregnancy. Change in paternity also
imparts increased risk of preeclampsia in multipara. Patients with
preeclampsia are more prone to vascular disease and chronic
hypertension later in life.
AIM OF THE STUDY
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AIM OF THE STUDY
? To study the ability of immediate postpartum curettage on
accelerated recovery from severe preeclampsia
? Effect on resolution of laboratory indices
MATERIALS AND
METHODS
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MATERIALS AND METHODS
SETTING RSRM Lying in hospital, Stanley,
Chennai
  DESIGN OF STUDY            Randomnised Prospective control study
 PERIOD OF STUDY            1 year
STUDY POPULATION       200 pregnant patients >28 weeks with
severe preeclampsia admitted in RSRM
Lying in hospital
INCLUSION CRITERIA
28 Weeks and above gestational age with either of the three
features of Severe PIH like:
1. BP of 160/110 and above at time of admisssion.
2. 2+ proteinuria in semi quantitative analysis.
3. less than 400 ml of urine output over 24 hours.
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As these features usually don’t exist consistently and concurrently
in all patients these additional criteria are taken such as altered
consciousness, headache, blurred vision, epigastric or right upper
quadrant pain, impaired liver function of unclear etiology,
thrombocytopenia.
EXCLUSION CRITERIA
1. < 28 Weeks of Gestation
2.  Mild PIH
3.  Cardiovascular and Renal Disorder
4.  Hypertension before Pregnancy
5. Convulsion Disorder and Liver Disorders
6.  Eclampsia.
METHODOLOGY
Sample size:
 200 pregnant women fulfilling the inclusion criteria of which100
undergoing Curettage and 100  not undergoing curettage. As per the
hospital records during, the last 5 years there were around two hundred
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cases of severe preeclampsia every year in RSRM LYING IN
HOSPITAL. With reference to that, two hundred cases were selected for
the present study as a convenience sampling. No formula was used for
sample size
Sampling Technique: Randomization
Pregnant women fulfilling the criteria will be selected by
randomization such as those with even numbers in intervention group and
those with odd numbers in the non intervention group. Thus 200
respondants will be selected for study purpose. The method of
randomisation is computer based random numbers.
METHOD OF COLLECTION OF DATA
The admission tests involve BP, proteinuria, platelet count, LFT,
RFT measurement of urine output. As a routine, the placental location is
noted as per USG to note the site for curettage. Data will be collected on
patients status regarding
? Cerebral and visual disturbances, headache and blurring of
vision
? Epigastric pain.
? Impaired liver function test of unclear etiology
? Thrombocytopenia.
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The study group will undergo curettage at vaginal or caesarean
delivery. At caesarean the presumed decidua basalis will be curetted with
large blunt curette. Patients who delivered vaginally will be curetted
under I.V sedation using large blunt curette . This study is done on
postpartum patients.
Post-partum surveillance will be done- for 48 hours. With 4 th
hourly BP recording, 4 th hourly urine output,  platelet count, LFT and
RFT 24 hourly
All medications given are noted. Patients  stay in CCU/Labour
ward is noted.
Patients are shifted to postoperative ward from CCU only if the
following criteria is fulfilled.
CRITERIA-
a) adequate diuresis(>100 ml/hr for atleast two consecutive hours)
b) BP   <150/100mm/Hg
c) Rising platelet count of >50,000/ml
OBSERVATIONAL
ANALYSIS
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OBSERVATIONAND ANALYSIS
TABULAR COLUMN 1 - AGE AND GESTAIONAL AGE
Group N Mean
Std.
Deviation
P value
Age in
years
Control 100 24.18 3.702
0.581
Cases 100 23.89 3.712
Gestational
age(wks)
Control 100 36.67 1.843
0.280
Cases 100 36.37 2.068
* The mean age and mean gestational age on admission was 24
years and 36 -37weeksfor both the control and study group. They
are statistically insignificant (NS) and hence both the control and
study group are comparable.
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TABULAR COLUMN 2-     PARITY
Group Total
Control Cases
Parity Primi Count 58 57 115
0.886
% within
Parity
50.4% 49.6% 100.0%
% within
Group
58.0% 57.0% 57.5%
Multi Count 42 43 85
% within
Parity
49.4% 50.6% 100.0%
% within
Group
42.0% 43.0% 42.5%
Total Count 100 100 200
% within
Parity
50.0% 50.0% 100.0%
% within
Group
100.0% 100.0% 100.0%
* Severe preeclampsia most commonly occurred in primigravida
constituting about 58% in control group and 57% in the study group with
a P value of .886 (NS).
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TABULAR COLUMN 3-MODE OF TERMINATION
Group Total P
Control Cases
.667
Mode of
termination
LSCS Count 60 57 117
% within Mode
of termination
51.3% 48.7% 100.0%
% within Group 60.0% 57.0% 58.5%
Normal Count 40 43 83
% within Mode
of termination
48.2% 51.8% 100.0%
% within Group 40.0% 43.0% 41.5%
Total Count 100 100 200
% within Mode
of termination
50.0% 50.0% 100.0%
% within Group 100.0% 100.0% 100.0%
* In this study about 57% in the study group and 60% in the
control group underwent LSCS while the remaining had a normal
vaginal delivery with a P value of .667 (NS).
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TABULAR COLUMN 4-URINE ALBUMIN ON ADMISSION
Group
Total
P
Control 74Cases
Urine albumin –
Pre
1+
Count 42 32 74
% within Urine
albumin – Pre
56.8% 43.2% 100.0%
.120
% within Group 42.0% 32.0% 37.0%
2+ Count 56 55 111
% within Urine
albumin – Pre
50.5% 49.5% 100.0%
% within Group 56.0% 55.0% 55.5%
3+ Count 12 13 25
% within Urine
albumin – Pre
83.3% 86.7% 100.0%
% within Group 12.0% 13.0% 12.5%
Total Count 100 100 200
% within Urine
albumin – Pre
50.0% 50.0% 100.0%
% within Group 100.0% 100.0% 100.0%
* On admission urine albumin was comparable in both the study
and control group with a P value of .120(NS)
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TABULAR COLUMN 5-Tablet LABETALOL ON ADMISSION
Group Total P
Control Cases
.121
Labetalol -
Pre
1
Count 19 13 32
% within
Labetalol –
Pre
68.1% 71.9% 100.0%
% within
Group
19.0% 13.0% 32.0%
2 Count 81 87 168
% within
Labetalol –
Pre
49.2% 45.8% 100.0%
% within
Group
81.0% 87.0% 169.0%
Total Count 100 100 200
% within
Labetalol –
Pre
50.0% 50.0% 100.0%
% within
Group
100.0% 100.0% 100.0%
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TABULAR COLUMN 6-Tablet NIFEDIPINE ON ADMISSION
* On admission antihypertensives like Tab Labetalol and Tab
Nifedipine  was given  equally to both study and control group
with a P value of .121 and <.232(NS)
Group Total P
Control Cases
Nifidepine –
Pre
1 Count 59 53 112
.232
% within
Nifidepine –
Pre
44.5% 55.5% 100.0%
% within
Group
59.0% 53.0% 112.0%
2 Count 41 47 88
% within
Nifidepine –
Pre
45.9% 54.1% 100.0%
% within
Group
41.0% 47.0% 88.0%
Total Count 100 100 200
% within Ni
fidepine – Pre
50.0% 50.0% 100.0%
% within
Group
100.0% 100.0% 100.0%
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TABULAR COLUMN 7-LABORATORY INVESTATIGATIONS
ON ADMISSION
Group N Mean Std. Deviation
Std. Error
Mean
p
Va;ue
SBP – Pre Control 100 158.50 6.416 .642
.204
Cases 100 156.80 11.710 1.171
DBP – Pre Control 100 106.60 7.278 .728
.605
Cases 100 106.10 6.340 .634
Urine output - Pre Control 100 85.00 34.304 3.430
.687
Cases 100 83.10 32.183 3.218
Platelet count
(lakhs/litre) – Pre
Control 100 1.435 .2463 .0246
.310
Cases 100 1.398 .2674 .0267
Bl.Urea (mg/dl) -
Pre
Control 100 23.90 6.209 .621
.833
Cases 100 23.73 5.120 .512
S.Creatinine (mg/dl)
– Pre
Control 100 .603 .1566 .0157
.894
Cases 100 .600 .1627 .0163
Uric acid (mg/dl) -
Pre
Control 100 6.832 .9125 .0913
.410
Cases 100 6.925 .9889 .0989
SGOT(mEq/L) - Pre Control 100 42.34 15.574 1.557
.964
Cases 100 42.22 21.294 2.129
SGPT(mEq/L) - Pre Control 100 42.26 16.673 1.667
.774
Cases 100 43.12 24.814 2.481
SAP(mEq/L) - Pre Control 100 97.52 25.924 2.592
.317Cases 100 102.23 39.101 3.910
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On admission the laboratory values of platelet count, urine output,
blood urea, serum creatine, SGOT, SGOT and SAP were found to be
within normal limits except for a  very few patients with elevated liver
enzymes and moderately reduced urine output in both the control group
and study group. The mean of each value in both the study and control
group are as follows:
SBP – Pre Control 158.50
Cases 156.80
DBP - Pre Control 106.60
Cases 106.10
Urine output – Pre Control 85.00
Case 83.10
Platelet count (lakhs/litre) – Pre Control 1.435
Cases 1.398
Bl.Urea (mg/dl) - Pre Control 23.90
Cases 23.73
S.Creatinine (mg/dl) – Pre Control .603
Cases .600
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Uric acid (mg/dl) - Pre Control 6.832
Cases 6.925
SGOT(mEq/L) - Pre Control 42.34
Cases 42.22
SGPT(mEq/L) - Pre Control 42.26
Cases 43.12
SAP(mEq/L) – Pre Control 97.52
Cases 102.23
Hence all these values have a P value of >.05 (NS) making them
comparable with each other.
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TABULAR COLUMN 8-INVESTIGATION REPORTS ON DAY 1
Group N Mean Std. Deviation
Std. Error
Mean
P value
SBP - Day 1 Control 100 152.70 6.795 .679
.000Cases 100 147.40 6.609 .661
DBP - Day 1 Control 100 99.90 5.773 .577
.000
Cases 100 96.00 4.924 .492
Urine output - Day 1 Control 100 91.00 31.286 3.129
.000
Cases 100 112.50 28.758 2.876
Platelet count (lakhs/litre) - Day 1 Control 100 1.448 .2359 .0236
.138
Cases 100 1.495 .2100 .0210
Bl.Urea (mg/dl) - Day 1 Control 100 23.89 5.896 .590
.060
Cases 100 22.57 3.740 .374
S.Creatinine (mg/dl) - Day 1 Control 100 .586 .1429 .0143
.103
Cases 100 .554 .1337 .0134
Uric acid (mg/dl) - Day 1 Control 100 6.657 .8059 .0806
.000
Cases 100 6.091 .8545 .0854
SGOT(mEq/L) - Day 1 Control 100 41.64 14.761 1.476
.087
Cases 100 38.03 14.906 1.491
SGPT(mEq/L) - Day 1 Control 100 41.07 14.869 1.487
.205
Cases 100 38.25 16.473 1.647
SAP(mEq/L) - Day 1 Control 100 93.53 17.400 1.740
.433
Cases 100 91.33 21.932 2.193
* On the first postnatal /postoperative day there is a significant fall
of BP and Serum Uric Acid and a moderate increase in urine output
in the study group who underwent curettage than those patients in
the control group
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TABULAR COLUMN 9-INVESTIGATION REPORTS ON DAY2
Group N Mean Std. Deviation
Std. Error
Mean P
SBP - Day 2 Control 100 148.10 5.979 .598 <.001
Cases 100 137.20 5.333 .533
DBP - Day 2 Control 100 95.60 5.379 .538 <.001
Cases 100 89.10 2.876 .288
Urine output - Day 2 Control 100 96.50 29.521 2.952 <.001
Cases 100 130.50 28.333 2.833
Platelet count (lakhs/lt) - Day 2 Control 100 1.495 .2508 .0251 .021
Cases 100 1.570 .2042 .0204
Bl.Urea (mg/dl) - Day 2 Control 100 23.38 5.763 .576 .002
Cases 100 21.32 3.390 .339
S.Creatinine (mg/dl) - Day 2 Control 100 .572 .1450 .0145 .010
Cases 100 .521 .1328 .0133
Uric acid (mg/dl) - Day 2 Control 100 6.536 .7713 .0771 <.001
Cases 100 5.243 .6663 .0666
SGOT(mEq/L) - Day 2 Control 100 41.30 14.487 1.449 <.001
Cases 100 34.00 6.566 .657
SGPT(mEq/L) - Day 2 Control 100 40.56 14.445 1.444 <.001
Cases 100 33.63 6.851 .685
SAP(mEq/L) - Day 2 Control 100 90.93 12.608 1.261 <.001
Cases 100 84.96 9.997 1.000
Mean and P Value of Each Investigations on Day 2
SBP (mm/Hg) P value
Control 148.10 <.001
    Cases 137.20
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DBP (mm/Hg)
Control 95.60 <.001
Cases 89.10
Urine output (ml/Hr)
Control 96.5 <.001
Cases 130.50
Platelet count(lakhs/cumm)
Control 1.495 .021
 Cases 1.570
Bl.Urea (mg/dl)
 Control 23.38 .002
 Cases 21.32
S.Creatinine (mg/dl)
Control .572 .010
 Cases .521
Uric acid (mg/dl)
Control 6.536 <.001
 Cases 5.243
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SGOT(mEq/L)
Control 41.30 <.001
Cases 34.00
SGPT(mEq/L)
Control 40.56 <.001
Cases 33.63
SAP(mEq/L)
Control 90.93 <.001
Cases 84.96
There is a significant decrease in BP, blood urea , serum creatinine,
uric acid and liver enzymes  with subsequent increase in urine output in
patients undergoing postpartum curettage ,except for platelet count which
was statistically insignificant.
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TABULAR COLUMN 10-Tablet LABETALOL DAY 2
Group Total P
Control Cases
.155
Labetalol - Day 2 1 Count 0 2 2
% within
Labetalol - Day
2
.0% 100.0% 100.0%
% within Group .0% 2.0% 1.0%
2 Count 100 98 198
% within
Labetalol - Day
2
50.5% 49.5% 100.0%
% within Group 100.0% 98.0% 99.0%
Total Count 100 100 200
% within
Labetalol - Day
2
50.0% 50.0% 100.0%
% within Group 100.0% 100.0% 100.0%
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TABULAR COLUMN 11-Tablet NIFEDIPINE DAY 2
Group Total P
Control Cases
<.001
Nifidepine -
Day 2
0 Count 16 88 104
% within
Nifidepine -
Day 2
15.4% 84.6% 100.0%
% within Group 16.0% 88.0% 52.0%
1 Count 30 12 42
% within
Nifidepine -
Day 2
71.4% 28.6% 100.0%
% within Group 30.0% 12.0% 21.0%
2 Count 54 0 54
% within
Nifidepine -
Day 2
100.0% .0% 100.0%
% within Group 54.0% .0% 27.0%
Total Count 100 100 200
% within
Nifidepine -
Day 2
50.0% 50.0% 100.0%
% within Group 100.0% 100.0% 100.0%
* There is no significant decrease in the dosage of tablet labetalol
while there is a significant decrease in the dosage of tablet
nifedipine (<.001) With 88% of patients in study group having
stopped tablet nifedipine
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TABULAR COLUMN 12- COMPARISON OF LAB VALUES ON ADMISSION
AND ON DAY2 IN CONTROL GROUP
Mean N Std. Deviation
Std. Error
Mean P
Pair 1 SBP – Pre 158.50 100 6.416 .642 <.001
SBP - Day 2 148.10 100 5.979 .598
Pair 2 DBP – Pre 106.60 100 7.278 .728 <.001
DBP - Day 2 95.60 100 5.379 .538
Pair 3 Urine output – Pre 85.00 100 34.304 3.430 .004
Urine output - Day
2
96.50 100 29.521 2.952
Pair 4 Platelet count
(lakhs/litre) – Pre
1.435 100 .2463 .0246
<.001
Platelet count
(lakhs/litre) - Day 2
1.495 100 .2508 .0251
Pair 5 Bl.Urea (mg/dl) –
Pre
23.90 100 6.209 .621
.001
Bl.Urea (mg/dl) -
Day 2
23.38 100 5.763 .576
Pair 6 S.Creatinine (mg/dl)
–Pre
.603 100 .1566 .0157
<.001
S.Creatinine (mg/dl)
- Day 2
.572 100 .1450 .0145
Pair 7 Uric acid (mg/dl) –
Pre
6.832 100 .9125 .0913
<.001
Uric acid (mg/dl) -
Day 2
6.536 100 .7713 .0771
Pair 8 SGOT(mEq/L) –
Pre
42.34 100 15.574 1.557
<.001
SGOT(mEq/L) -
Day 2
41.30 100 14.487 1.449
Pair 9 SGPT(mEq/L) – Pre 42.26 100 16.673 1.667 <.001
SGPT(mEq/L) -
Day 2
40.56 100 14.445 1.444
Pair 10 SAP(mEq/L) – Pre 97.52 100 25.924 2.592 <.001
SAP(mEq/L) - Day
2
90.93 100 12.608 1.261
* There is a significant decrease in BP, urea ,creatinine, uric acid
and liver enzymes with increase in urine output and platelet count in the
control group.
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TABULAR COLUMN 13-COMPARISON OF LAB VALUES IN
STUDY GROUP ON ADMISSION AND DAY2
Mean N Std. Deviation Std. Error Mean P
Pair 1 SBP – Pre 158.50 100 6.416 .642 <.001
SBP - Day 2 148.10 100 5.979 .598
Pair 2 DBP – Pre 106.60 100 7.278 .728 <.001
DBP - Day 2 95.60 100 5.379 .538
Pair 3 Urine output – Pre 85.00 100 34.304 3.430 .004
Urine output - Day 2 96.50 100 29.521 2.952
Pair 4 Platelet count (lakhs/litre) – Pre 1.435 100 .2463 .0246 <.001
Platelet count (lakhs/litre) - Day 2 1.495 100 .2508 .0251
Pair 5 Bl.Urea (mg/dl) – Pre 23.90 100 6.209 .621 .001
Bl.Urea (mg/dl) - Day 2 23.38 100 5.763 .576
Pair 6 S.Creatinine (mg/dl) – Pre .603 100 .1566 .0157 <.001
S.Creatinine (mg/dl) - Day 2 .572 100 .1450 .0145
Pair 7 Uric acid (mg/dl) – Pre 6.832 100 .9125 .0913 <.001
Uric acid (mg/dl) - Day 2 6.536 100 .7713 .0771
Pair 8 SGOT(mEq/L) – Pre 42.34 100 15.574 1.557 <.001
SGOT(mEq/L) - Day 2 41.30 100 14.487 1.449
Pair 9 SGPT(mEq/L) – Pre 42.26 100 16.673 1.667 <.001
SGPT(mEq/L) - Day 2 40.56 100 14.445 1.444
Pair 10 SAP(mEq/L) – Pre 97.52 100 25.924 2.592 <.001
SAP(mEq/L) - Day 2 90.93 100 12.608 1.261
* Similar to control group the study group also shows a significant
decrease in BP, urea, creatinine, uric acid and liver enzymes with
significant increase in urine output and platelet count.
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TABULAR COLUMN 14- URINE ALBUMIN FOR CONTROL
AND STUDY GROUP ON ADMISSION AND ON DAY 2
Group Urine albumin - Day 2 Total P
Trace Mild Moderate
Control
Urine albumin –
Pre
Mild Count 19 23 0 42 <.001
% within Urine albumin - Pre 45.2% 54.8% .0% 100.0%
% within Urine albumin -
Day 2
76.0% 37.7% .0% 42.0%
Moderate Count 6 38 12 56 <.001
% within Urine albumin - Pre 10.7% 67.9% 21.4% 100.0%
% within Urine albumin -
Day 2
24.0% 62.3% 85.7% 56.0%
Severe Count 0 0 2 2 <.001
% within Urine albumin – Pre .0% .0% 100.0% 100.0%
% within Urine albumin -
Day 2
.0% .0% 14.3% 2.0%
Total Count 25 61 14 100
% within Urine albumin - Pre 25.0% 61.0% 14.0% 100.0%
% within Urine albumin -
Day 2
100.0% 100.0% 100.0% 100.0%
Cases
Urine albumin –
Pre
Mild Count 28 4 0 32 <.001
% within Urine albumin – Pre 87.5% 12.5% .0% 100.0%
% within Urine albumin -
Day 2
48.3% 10.0% .0% 32.0%
Moderate Count 30 25 0 55 <.001
% within Urine albumin - Pre 54.5% 45.5% .0% 100.0%
% within Urine albumin -
Day 2
51.7% 62.5% .0% 55.0%
Severe Count 0 11 2 13 <.001
% within Urine albumin - Pre .0% 84.6% 15.4% 100.0%
% within Urine albumin -
Day 2
.0% 27.5% 100.0% 13.0%
Total Count 58 40 2 100
% within Urine albumin - Pre 58.0% 40.0% 2.0% 100.0%
% within Urine albumin -
Day 2 100.0% 100.0% 100.0% 100.0%
* There is a significant decrease in urine albumin in both the groups.
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TABULAR COLUMN 15-DURATION OF STAY IN CCU/LABOUR
WARD
Group Total P
Control Cases
<.001
Duration of stay 1 Count 0 6 6
% within
Duration of stay
.0% 100.0% 100.0%
% within Group .0% 6.0% 3.0%
2 Count 52 94 146
% within
Duration of stay
35.6% 64.4% 100.0%
% within Group 52.0% 94.0% 73.0%
3 Count 39 0 39
% within
Duration of stay
100.0% .0% 100.0%
% within Group 39.0% .0% 19.5%
4 Count 9 0 9
% within
Duration of stay
100.0% .0% 100.0%
% within Group 9.0% .0% 4.5%
Total Count 100 100 200
% within
Duration of stay
50.0% 50.0% 100.0%
% within Group 100.0% 100.0% 100.0%
* There is a significant decrease (<.001) in the duration of stay in
the study group due to rapid fall of BP and improvement of
laboratory values.
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DISCUSSION
AGE AND GESTATIONAL AGE IN STUDY AND CONTROL
GROUP
? The average age in both the study and control group was 23-24
years
? While the gestational age was 36-37 weeks in both the study and
control group
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PARITY
? Severe preeclampsia was most commonly seen in primigravida
? Cases-57% was primigravida
? Controls-58% was primigravida
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MODE OF TERMINATION
? In this study 57% of cases and 60% of controls had LSCS while the
remaining patients had a normal vaginal delivery(NVD).
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SYSTOLIC BLOOD PRESSURE
? The systolic blood pressure in the study group decreases from a
mean value of 156mm/Hg to 147mm/Hg in the first postpartum
day which further decreases to 137mm/Hg in the second
postpartum day.
? The systolic blood pressure in the control group decreases from a
mean value of 158mm/Hg to 152mm/Hg in the first postpartum
day which further decreases to 148mm/Hg in the second
postpartum day indicating a rapid recovery following curettage.
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DIASTOLIC BLOODPRESSURE
? The diastolic blood pressure in the study group decreases from a
mean value of 106mm/Hg to 96mm/Hg in the first postpartum day
which further decreases to 89mm/Hg in the second postpartum day.
? The diastolic blood pressure in the control group decreases from a
mean value of 106mm/Hg to 99mm/Hg in the first postpartum day
which further decreases to 95mm/Hg in the second postpartum day
indicating a rapid recovery following curettage.
80
85
90
95
100
105
110
CASES CONTROL
106 106
96
99
89
95
BP in mm/Hg
PRE DAY 1 DAY 2
69
URINE OUTPUT
? The urine output in cases increased from a mean of 83ml/hr in the
cases to about 130ml/hr in the second postpartum day when
compared to the control group where the increase was just from a
mean of 85ml/hr to 96ml/hr in the second postpartum day
indicating an increase of about 25% in the study group when
compared to the control group with a significant P value of <.001
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PLATELET COUNT
? The platelet count increased in both the study and control group  .
The percentage of increase was found to be 13% in the study group
and 4%in the control group indicating an increase of platelet count
by 9% in the study group compared to the control  group with a P
value of .021 which is significant.
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BLOOD UREA
? The decrease in blood urea was about 8% in the study group when
compared to the control group which had a decrease of only 2%
although all the patients in both the control and study group had
blood urea levels within the normal limit with a P value of .002
which is significant.
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SERUM CREATININE
? The decrease in serum creatinine was about 13% in the study group
when compared to the control group which had a decrease of only
5% although all the patients in both the control and study group
levels had  serum creatinine within the normal limit with a P value
of .010 which is significant.
0% 20% 40% 60% 80% 100%
CASES
CONTROLS
CASES CONTROLS
PRE 0.6 0.6
DAY1 0.55 0.58
DAY2 0.52 0.57
SERUM CREATINE in mg/dl
73
SERUM URIC ACID
? The serum uric acid in cases decreased from a mean of 6.9mg/dl in
the cases to about5.2mg/dl in the second postpartum day when
compared to the control group where the decrease was just from a
mean of 6.8mg/dl to 6.5mg/dl in the second postpartum day
indicating a decrease of about 20% in the study group when
compared to the control group with a significant P value of <.001.
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SGOT
? The decrease in the SGOT value in the study group was about 19%
when compared to the control group which had a decrease of only
2% with a P value of <.001 which is highly significant.
CASES CONTROLS
42 42
38 41
34 40
SGOT in IU/L
PRE DAY1 DAY2
75
SGPT
? The decrease in the SGPT value in the study group was about 23%
when compared to the control group which had a decrease of only
4% with a P value of <.001 which is highly significant.
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SAP
? The decrease in the SAP value in the study group was about 18%
when compared to the control group which had a decrease of only
7% with a P value of <.001 which is highly significant
CASES CONTROLS
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PERCENTAGE OF DIFFERENCE OF THE VALUES
MONITORED ON ADMISSION AND ON DAY2 IN BOTH
CONTROL AND CASES
? From this study it is seen that there is a significant difference
between the cases and controls as follows
? Systolic blood pressure(SBP) decreased by 12%in the study group
when compared to the control group which had a decrease of only
6% with a p value of <.001
? Diastolic blood pressure(DBP) decreased by 16% in the study
group compared to the control group with a decrease of about 10%
? Urine output(U/O) increased by 36% in the study group while the
control group had an increase of 11% with a p value <.001.
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? Platelet count(PLAT) had a increase of 13% in the study group and
4% in the control group with a p value of .021
? Blood urea had a decrease of 8% in the study group and 2% in the
control group with a significant p value of.002
? Creatinine (CREAT) had a decrease of 13% in the study group
with only 5% decrease in the in the control group with a p value of
.010
? Serum uric acid (U.ACID) had a decrease of 24% in study group
and only 4% decrease in control group with a p value of <.001.
? Liver enzymes also had a significant decrease in the study group
when  compared to the control group with a p value of <.001
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SGOT :  cases  -decreased by  28%
Controls –decreased by 2%
 SGPT :  cases  -decreased by  23%
Controls –decreased by 4%
SAP    :  cases  -decreased by  17%
              Controls –decreased by 11%
CONCLUSION
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CONCLUSION
Preeclampsia is the one of the leading cause of maternal death
worldwide. It constitutes about 22% of all perinatal deaths and about 30%
of maternal deaths in developed countries. Intracranial bleeding is the
leading cause of maternal death in preeclampsia.
        The morbidity of severe preeclampsia can be prevented by early
treatment and accelerated recovery from preeclampsia.
          This study states that postpartum curettage is a safe and effective
procedure which accelerates recovery from preeclampsia averting
complications and decreasing the mortality and morbidity associated with
severe preeclampsia.
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CONSENT FORMS
INFORMED CONSENT FORM
Hypertensive disorders during pregnancy continue to be a major cause
of maternal and perinatal morbidity and mortality worldwide .In
developing countries they are second only to anaemia with approximately
3-10% of all pregnancies.
 Preeclampsia resolves only after all gestational products
particularly the placenta and decidua have been removed or have ceased
to function. Therefore removal is the best means of cure of the disease.
We consider the above theory and therefore by immediate post partum
curettage we try to remove all the decidual tissues therefore hastening the
recovery.  This  study  is  to  observe  the  effects  of  immediate  post  partum
curettage on resolution of clinical and laboratory indices associated with
severe PIH and eclampsia .The identity of the patients will be kept
confidential.
INFORMED CONSENT FORM
STUDY TITLE : “.ABILITY OF POSTPARTUM CURETTAGE
TO ACCELERATE MATERNAL
RECOVERY IN SEVERE PREECLAMPSIA
PATIENTS”
STUDY CENTRE :    RSRM Lying in hospital , Royapuram,Chennai
Patient may check (?) these boxes.
Participant  Name :     Age:               I.P.no:
I confirm that I have understood the purpose of the above study. I have
the opportunity to ask the question and all my questions and doubts have
been answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I am
free to withdraw at any time without giving any reason, without my legal
rights being affected.
I understand that investigator, the institution, regulatory authorities and
the ethics committee will not need my permission to look at my health
records both in respect to the current study and any further research that
may be conducted in relation to it, even if I withdraw from the study.
I understand that my identity will not be revealed in any information
released to third parties or published, unless as required under the law. I
agree not to restrict the use of any data or results that arise from this
study.
I hereby consent to undergo complete physical examination diagnostic
tests including hematological, biochemical, radiological and urine
examinations and intervention surgical procedure like curettage.
I  hereby  consent  to  participate  in  this  study  of  “ABILITY  OF
POSTPARTUM CURETTAGE TO ACCELERATE MATERNAL
RECOVERY IN SEVERE PREECLAMPSIA  PATIENTS.”
Signature of patient /gaurdian: .......................................
Place ..............................Date………….............
Address
……….…………………….…
………………………………...
Signature of investigator............................
place:……………………….date………………..
PROFORMA
PROFORMA
S.No: Unit:
NAME: AGE:                                       I.P.No:
OCCUPATION: INCOME:
SOCIO ECONOMIC STATUS:
RESIDENCE:
PRESENTING HISTORY :-
OBSTETRIC INDEX LMP:                               EDD
pedal edema,  pain abdomen, bleeding / draining per vaginum,
perception of fetal movements , epigastric pain ,headache, nausea,
vomiting ,decreased urine output, blurring of vision
MENSTRUAL HISTORY                    Menarche:      Regular /Irreg.
LMP:             EDD:
MARITAL HISTORY
OBSTETRIC HISTORY
LCB
Previous Obstetric Performance
1. History of IUD
2. History of IUGR
3. H/o.PIH in the previous pregnancy
4. H/O  miscarriages
OTHER COMPLICATIONS ASSOCIATED
1. Anaemia
2. Heart disease
3. Gestational diabetes mellitus
4. RH negative pregnancy
5. IUGR
CLINICAL EXAMINATION
Ht : Wt:
Anaemia
 Edema Legs
 PR:                                                     CVS:
 BP:                                                     RS:
ABDOMINAL  EXAMINATION
Uterine size in gestatational weeks
FH
LIQUOR CLINICALLY
PV
INVESTIGATIONS
Urine :
Alb:
Sugar and deposits:
24 our urinary  protein
Blood  :
Hb %:                                       LFT                                                  RFT
PCV Srbilurubin                                Urea
Platelets  total protein                            Srcreat
Sr albumin
BT/CT                                    SGOT
Gr/ Typing:                          SGPT
SAP
ULTRASONOGRAM
BPD
FL:
HC:
AC:    LIQUOR:
PLACENTA:
MODE OF DELIVERY: CAESAREAN / VAGINAL DELIVERY
POST PARTUM CURETTAGE: DONE        /     NOT DONE
ANTIHYPERTENSIVES GIVEN
MONITORING PATIENTS IN POSTPARTUM PERIOD
BP MONITORING EVERY 4th HOURLY
DAY1 BP
DAY2 BP
MONITORING URINE OUTPUT AND URINE ALBUMIN 4th
HOURLY
DAY1 U/O
U/A
DAY2 U/O
U/A
MONITORING LABORATORY VALUES DAILY
PL
A
T
U
R
E
A
C
R
E
A
T
U
R
IC
A
C
ID
Day1
Day2
SGOT SGPT SAP
Day1
Day2
DURATION OF STAY IN CCU/LABOUR WARD:
ABBREVATIONS
ABBREVIATIONS
NK : Natural killer
HLA-G : Human leucocyte antigen G
sFlt : soluble Fms like tyrosine kinase
sEng : soluble endoglin
ROS : Reactive oxygen species
AGEs : Activated Glycogen end products
NO : Nitric oxide
PlGF : Placental growth factor
VEGF : Vascular endothelial growth factor
TGF : Transforming growth factor
NICE : National Institute of Clinical Excellence
PCV : Packed cell volume
Beta HCG : beta Human chorionic gonadotrophin
PAPP-A : Pregnancy associated plasma protein
CLASP : Collaborative low dose aspirin study
TGL : Triglyceride
LDL : Low density lipoprotein
BMI : Body mass index
ESRD : End stage renal disease
IUGR : Intrauterine growth restriction
SGOT(AST) : Serum glutamic oxaloacetic transaminase
(Aspartate transaminase)
SGPT (ALT) : Serum glutamic pyruvic transaminase
(Alanine transaminase)
SAP : Serum alkaline phosphatase
LDH : Lactate dehydrogenase
CTG : Cardiotocogram
APLA : Antiphospholipid antibody syndrome
CCU : Critical care unit
NS : Not significant

 MASTER CHART
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1 23 Primi 37 160 110 1 100 1 24 0.8 7.8 32 36 97 2 2 LSCS 150 100 1 100 1.5 24 0.8 6.2 32 36 96 2 2 140 90 trace 150 1.5 23 0.7 5.9 32 36 95 2 2
2 28 Primi 37 160 110 2 50 1.2 22 0.7 7.2 34 30 95 2 2 LSCS 150 90 1 100 1.2 21 0.7 6 32 30 95 2 1 140 90 1 100 1.3 20 0.7 4.8 32 30 95 2 2
3 27 Primi 38 150 100 2 100 1.4 26 0.6 6.3 28 25 87 2 2 LSCS 140 90 1 150 1.5 26 0.6 4.2 28 25 86 2 130 90 trace 150 1.5 25 0.6 4 28 25 86 2 1
4 20 Primi 30 headache, decreased urine output 170 120 3 30 1 30 0.9 9.2 72 78 186 2 2 + NVD 150 100 2 50 1.4 28 0.8 5.8 69 63 150 2 2 + 140 90 1 100 1.7 23 0.7 4.1 42 40 97 2 1 2
5 20 G3P2L2 35 headache 160 120 2 50 1.2 23 0.8 6.8 99 99 192 1 1 + LSCS 160 90 trace 100 2 23 0.8 5 83 78 137 2 1 + 130 90 trace 150 2.1 22 0.6 4 45 48 94 2 2
6 21 Primi 37 150 110 2 100 1.8 18 0.5 6 43 35 75 1 1 LSCS 140 100 1 100 1.8 18 0.5 4.9 43 35 74 2 1 130 90 trace 100 1.8 16 0.4 4.7 42 35 74 2 2
7 22 Primi 37 150 100 3 150 1.5 18 0.5 5.9 34 38 66 2 2 LSCS 140 90 2 150 1.5 18 0.5 5.8 33 37 90 2 130 80 1 200 1.6 18 0.4 4.9 33 37 90 1 2
8 20 Primi 38 170 110 2 100 1.6 26 0.6 6.8 39 37 91 2 2 + LSCS 150 100 1 150 1.6 25 0.6 6.6 39 37 90 2 2 + 140 90 trace 150 1.7 26 0.6 5 39 37 90 2 2
9 19 Primi 35 160 100 1 100 1.5 18 0.5 7.2 31 35 91 2 2 NVD 150 100 1 100 1.5 18 0.5 7.1 30 35 91 2 2 150 90 1 150 1.5 16 0.5 6.1 30 35 91 2 1 2
10 20 Primi 36 150 110 2 100 1.8 20 0.5 7.9 32 34 82 2 2 NVD 140 100 1 100 1.8 20 0.5 6.8 32 34 80 2 1 140 90 1 100 2 18 0.5 5.9 32 34 80 2 2
11 26 G3P1L1D1 37 150 100 2 50 1.4 22 0.4 7 49 45 98 2 2 LSCS 140 90 2 100 1.6 22 0.3 6 44 43 95 2 130 90 1 150 1.6 21 0.4 5.1 42 42 94 2 1
12 28 G2P1L1` 37 150 100 2 50 1.5 24 0.6 6.8 36 38 87 2 2 NVD 140 100 2 100 1.5 24 0.5 5.9 34 36 87 2 1 140 90 1 100 1.5 24 0.5 5.7 34 35 86 2 2
13 25 G2P1L1 36 160 100 2 100 1.7 26 0.5 6.4 34 39 89 2 2 NVD 140 90 1 150 1.6 25 0.5 6 34 36 88 2 130 90 trace 150 1.7 25 0.5 5.4 32 34 87 2 2
14 24 Primi 37 60 100 2 100 1.9 28 0.7 6.2 22 28 89 2 2 LSCS 150 100 1 100 1.9 28 0.7 5.8 22 27 87 2 2 140 90 trace 100 2 28 0.7 5 22 27 87 2 1 2
15 23 Primi 37 160 100 2 100 1.6 20 0.6 6.6 35 30 88 2 2 LSCS 150 100 2 100 1.6 20 0.6 6 35 29 87 2 2 130 90 1 150 1.6 18 0.5 5.1 35 28 86 2 1 2
16 20 Primi 38 150 100 2 100 1.5 18 0.5 6.1 34 31 96 2 2 LSCS 140 100 1 150 1.5 18 0.5 5.4 34 31 90 2 1 130 90 1 150 1.6 17 0.5 5 34 31 90 2 2
17 20 Primi 37 headache, decreased urine output 150 110 3 30 1 32 0.9 8.8 72 69 158 1 1 + LSCS 140 100 2 100 1.3 26 0.8 6.6 43 40 98 2 1 + 130 90 1 150 1.5 25 0.6 5.3 40 39 96 2 2
18 21 Primi 37 160 110 1 100 1.5 28 0.5 7 36 31 85 1 1 LSCS 150 90 1 100 1.5 24 0.5 6.2 35 31 80 2 1 140 90 trace 150 1.6 22 0.4 5.9 34 30 80 2 2
19 21 Primi 36 150 100 2 50 1.4 26 0.4 6.8 38 32 97 1 1 LSCS 140 100 1 100 1.3 24 0.3 6.1 35 32 95 2 1 140 90 trace 100 1.5 20 0.3 5.8 35 32 94 2 2
20 22 G2P1L1 37 160 100 1 100 1.3 25 0.6 6.1 39 35 87 2 2 LSCS 150 90 trace 150 1.4 25 0.6 5.7 37 35 86 2 1 140 80 trace 150 1.4 25 0.5 5.7 37 34 84 2 2
21 20 Primi 37 160 100 1 100 1.2 24 0.5 6.6 37 29 78 2 2 LSCS 150 90 1 150 1.2 24 0.5 6.5 37 29 77 2 1 140 90 trace 150 1.2 24 0.5 6 37 29 77 2 2
DAY   2DAY    1CASES - CURETTAGE DONE PATIENTS
22 21 Primi 38 150 100 1 50 1.6 25 0.4 5.9 29 23 99 1 1 LSCS 140 100 1 100 1.6 25 0.4 5.8 28 21 78 2 2 130 90 trace 100 1.6 20 0.4 5 28 21 78 2 2
23 24 G2P1L1 32 headache ,decreased urine output 170 100 3 30 1 30 0.9 9.7 101 143 200 2 2 + NVD 150 100 2 50 1.6 26 0.6 8.3 72 101 143 2 1 + 140 90 2 100 1.8 23 0.5 6.2 46 52 98 2 1 2
24 23 G2P1L1 40 160 100 2 100 1.5 20 0.4 7.1 24 29 67 2 2 NVD 150 90 1 150 1.7 20 0.4 6.9 24 29 65 2 2 140 90 1 150 1.7 20 0.4 6.3 24 29 65 2 2
25 22 Primi 35 headache, blurring of vision 160 110 2 100 1 28 0.6 7.2 76 78 165 2 2 + LSCS 150 100 1 100 1.3 26 0.6 6.5 45 50 107 2 1 + 140 90 1 150 1.6 25 0.6 5.9 40 40 99 2 1 2
26 23 Primi 37 160 100 1 100 1.6 18 0.5 6.8 29 23 71 1 1 LSCS 160 90 1 100 1.6 18 0.5 6.7 29 23 70 2 1 150 80 trace 100 1.6 18 0.4 6.3 29 23 70 2 2
27 20 Primi 36 160 110 1 50 1.4 20 0.4 6.6 23 20 68 2 2 LSCS 140 100 1 50 1.4 20 0.4 6 20 20 68 2 1 130 90 trace 100 1.4 20 0.3 5.8 20 19 67 2 1
28 21 G3P1L1A1 37 150 110 2 100 1.2 18 0.6 5.9 35 37 95 2 2 LSCS 140 100 1 150 1.2 18 0.6 5.7 35 36 94 2 1 130 90 trace 150 1.4 16 0.5 5.5 35 36 93 2 1
29 19 Primi 34 150 110 2 100 1.4 22 0.7 6.6 29 21 78 2 2 NVD 140 100 1 100 1.4 22 0.7 5.8 28 20 78 2 1 130 90 1 150 1.6 20 0.6 4.9 25 20 76 2 2
30 18 Primi 37 160 110 1 100 1.6 24 0.5 6.9 30 35 91 2 2 LSCS 140 100 trace 100 1.6 22 0.5 5 30 35 90 2 1 140 90 trace 100 1.8 22 0.5 4.6 30 35 90 2 2
31 20 G2P1L1 37 160 110 1 100 1.2 24 0.7 7.6 32 38 96 2 1 NVD 160 100 1 100 1.2 24 0.7 6.9 32 38 95 2 1 140 90 trace 150 1.3 22 0.6 5.1 32 38 95 2 2
32 24 G2P1L1 36 150 100 2 50 1.3 26 0.6 6.3 26 25 85 2 1 NVD 140 90 1 100 1.3 25 0.6 5.9 26 25 85 1 130 90 1 100 1.3 25 0.6 4.2 26 25 85 2 2
33 25 G2P1L1 38 160 120 2 100 1.1 25 0.6 6 28 27 98 2 2 + NVD 150 100 1 150 1.1 25 0.5 5.1 28 27 96 2 1 + 140 90 trace 150 1.2 25 0.5 4.7 28 27 95 2 2
34 18 Primi 38  headache,decreased  urine output, 170 110 3 30 1 35 0.9 8.8 72 71 183 2 2 + LSCS 150 100 2 50 1.3 28 0.7 7.9 55 51 155 2 1 + 140 90 1 100 1.5 26 0.7 6 43 39 82 2 2
35 20 Primi 34 150 110 2 100 1.5 21 0.5 6.2 31 39 73 2 1 NVD 140 90 1 100 1.4 20 0.5 5.5 31 35 70 1 130 80 trace 100 1.2 20 0.9 5 31 35 70 2 2
36 21 Primi 37 160 110 1 50 1.4 23 0.3 6.3 29 29 74 2 1 LSCS 150 100 1 100 1.4 22 0.3 5.1 29 28 74 2 1 140 90 trace 100 1.5 21 0.3 4.8 29 28 74 2 2
37 23 Primi 38 150 110 1 100 1.6 18 0.7 5.9 37 35 95 2 1 LSCS 140 100 trace 100 1.6 18 0.6 5 37 34 94 2 1 140 90 trace 100 1.7 18 0.6 4.5 37 34 94 2 2
38 26 G3P1L1A1 36 160 110 1 150 1.5 20 0.6 6.8 30 38 93 1 1 LSCS 150 100 1 150 1.5 20 0.5 6.5 30 36 93 2 1 140 90 1 200 1.6 19 0.5 4.9 30 36 93 2 2
39 22 Primi 35 160 100 2 150 1.4 20 0.6 6.5 30 34 96 1 1 NVD 160 90 1 150 1.4 20 0.6 6 30 34 95 2 1 140 90 trace 150 1.5 20 0.5 5 30 32 92 2 2
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40 21 Primi 34 headache 150 110 2 100 1.8 18 0.5 5.9 35 39 71 1 1 + NVD 140 100 1 100 1.9 18 0.5 5 34 36 69 2 1 + 130 90 trace 150 1.9 18 0.5 4.5 34 36 94 2 2
41 20 primi 37 epigastric pain ,decreased urine output 160 120 3 30 1 36 0.9 8.9 101 107 206 2 1 + LSCS 150 100 2 150 1.5 30 0.7 7.2 88 86 154 2 1 + 140 90 1 100 1.6 26 0.7 6.1 46 40 96 2 2
42 19 Primi 38 170 100 2 100 1.2 22 0.4 5.8 28 25 78 2 1 + LSCS 150 90 1 100 1.2 21 0.4 5 28 25 76 2 1 + 140 90 1 100 1.4 21 0.3 4.8 28 25 76 2 2
43 25 G2P1L1 37 160 100 2 100 1.3 24 0.7 5.7 37 39 76 2 1 LSCS 150 90 1 150 1.4 23 0.6 4.9 35 37 75 2 1 140 90 trace 150 1.4 22 0.6 4.3 35 37 75 2 2
44 24 G2P1L1 30 epigastric pain ,blurring of vision 160 110 1 50 1.5 17 0.6 6.8 95 98 164 2 1 + NVD 150 100 trace 100 1.5 17 0.5 6.5 72 78 111 2 1 + 140 90 trace 100 1.5 16 0.5 5.9 50 49 93 2 2
45 28 G3P2L2 37 150 110 2 100 1.9 16 0.3 6.5 24 25 66 2 1 LSCS 150 100 1 100 1.9 15 0.3 6 24 24 65 2 1 140 90 trace 150 1.4 15 0.2 5.3 24 24 65 2 2
46 29 G2P1L1 32 160 100 2 100 1.8 16 0.4 6.4 37 39 72 2 1 NVD 140 100 1 150 1.8 16 0.4 5.9 35 37 72 2 1 130 90 trace 150 2 15 0.4 4 35 37 72 2 2
47 20 Primi 37 headache ,decreased urine output 170 100 2 40 1 35 0.8 8.7 39 40 86 2 1 + LSCS 160 90 1 100 1.3 30 0.7 7.9 38 40 80 2 1 + 140 90 1 100 1.5 26 0.7 6.1 35 39 80 2 2
48 19 Primi 36 headache ,decreased urine output 160 110 2 50 1 33 0.8 8.5 61 59 164 2 1 + NVD 150 90 1 100 1.2 29 0.6 7.8 56 56 103 2 1 + 140 90 1 100 1.4 25 0.6 6 42 40 80 2 2
49 27 Primi 37 160 100 1 100 1.7 20 0.7 6.6 31 33 74 2 1 LSCS 160 90 trace 150 1.7 20 0.6 6.6 31 32 72 2 1 140 90 trace 150 1.7 20 0.5 5.3 31 30 70 2 2
50 25 Primi 38 160 110 1 100 1.6 21 0.7 6.5 22 26 66 2 1 LSCS 150 100 trace 100 1.6 21 0.6 5.5 22 26 66 2 1 140 90 trace 150 1.6 19 0.6 4.8 22 25 64 2 2
51 20 Primi 34 decreased urine output, 150 110 3 30 1 32 0.9 8.8 72 69 158 1 1 + NVD 140 100 2 100 1.3 26 0.8 6.6 43 40 98 2 1 + 130 90 1 150 1.5 25 0.6 5.3 40 39 96 2 2
52 21 G2A1 36 160 110 1 100 1.5 28 0.5 7 36 31 85 1 1 LSCS 150 90 1 100 1.5 24 0.5 6.2 35 31 80 2 1 140 90 trace 150 1.6 22 0.4 5.9 34 30 80 2 2
53 24 G3A2 38 150 100 2 50 1.4 26 0.4 6.8 38 32 97 1 1 LSCS 140 100 1 100 1.3 24 0.3 6.1 35 32 95 2 1 140 90 trace 100 1.5 20 0.3 5.8 35 32 94 2 2
54 26 Primi 37 160 100 1 100 1.3 25 0.6 6.1 39 35 87 2 2 LSCS 150 90 trace 150 1.4 25 0.6 5.7 37 35 86 2 1 140 80 trace 150 1.4 25 0.5 5.7 37 34 84 2 2
55 23 Primi 38 160 100 1 100 1.2 24 0.5 6.6 37 29 78 2 2 LSCS 150 90 1 150 1.2 24 0.5 6.5 37 29 77 2 1 140 90 trace 150 1.2 24 0.5 6 37 29 77 2 2
56 19 Primi 34 150 110 1 50 1.6 25 0.4 5.9 29 23 99 1 1 NVD 140 100 1 100 1.6 25 0.4 5.8 28 21 78 2 2 130 90 trace 100 1.6 20 0.4 5 28 21 78 2 2
57 20 G2P1L0 30 headache , 170 100 3 30 1 30 0.9 9.7 101 143 200 2 2 + NVD 150 100 2 50 1.6 26 0.6 8.3 72 101 143 2 1 + 140 90 2 100 1.8 23 0.5 6.2 46 52 98 2 1 2
58 24 G2P1L1 34 160 100 2 100 1.5 20 0.4 7.1 24 29 67 2 2 NVD 150 90 1 150 1.7 20 0.4 6.9 24 29 65 2 2 140 90 1 150 1.7 20 0.4 6.3 24 29 65 2 2
59 25 G2A1 36 160 110 2 100 1 28 0.6 7.2 76 78 165 2 2 + LSCS 150 100 1 100 1.3 26 0.6 6.5 45 50 107 2 1 + 140 90 1 150 1.6 25 0.6 5.9 40 40 99 2 1 2
60 27 Primi 37 160 100 1 100 1.6 18 0.5 6.8 29 23 71 1 1 LSCS 160 90 1 100 1.6 18 0.5 6.7 29 23 70 2 1 150 80 trace 100 1.6 18 0.4 6.3 29 23 70 2 2
DAY   2DAY    1CASES - CURETTAGE DONE PATIENTS
61 26 G3P2L2 38 160 110 1 100 1.2 24 0.7 7.6 32 38 96 2 1 NVD 160 100 1 100 1.2 24 0.7 6.9 32 38 95 2 1 140 90 trace 150 1.3 22 0.6 5.1 32 38 95 2 2
62 25 G2P1L1 40 150 100 2 50 1.3 26 0.6 6.3 26 25 85 2 1 NVD 140 90 1 100 1.3 25 0.6 5.9 26 25 85 1 130 90 1 100 1.3 25 0.6 4.2 26 25 85 2 2
63 24 Primi 39 160 120 2 100 1.1 25 0.6 6 28 27 98 2 2 + LSCS 150 100 1 150 1.1 25 0.5 5.1 28 27 96 2 1 + 140 90 trace 150 1.2 25 0.5 4.7 28 27 95 2 2
64 20 Primi 32  headache,decreased  urine output, 170 110 3 30 1 35 0.9 8.8 72 71 183 2 2 + NVD 150 100 2 50 1.3 28 0.7 7.9 55 51 155 2 1 + 140 90 1 100 1.5 26 0.7 6 43 39 82 2 2
65 24 G2A1 40 150 110 2 100 1.5 21 0.5 6.2 31 39 73 2 1 LSCS 140 90 1 100 1.4 20 0.5 5.5 31 35 70 1 130 80 trace 100 1.2 20 0.9 5 31 35 70 2 2
66 23 Primi 37 160 110 1 50 1.4 23 0.3 6.3 29 29 74 2 1 LSCS 150 100 1 100 1.4 22 0.3 5.1 29 28 74 2 1 140 90 trace 100 1.5 21 0.3 4.8 29 28 74 2 2
67 19 Primi 34 150 110 1 100 1.6 18 0.7 5.9 37 35 95 2 1 NVD 140 100 trace 100 1.6 18 0.6 5 37 34 94 2 1 140 90 trace 100 1.7 18 0.6 4.5 37 34 94 2 2
68 20 G2A1 38 160 110 1 150 1.5 20 0.6 6.8 30 38 93 1 1 LSCS 150 100 1 150 1.5 20 0.5 6.5 30 36 93 2 1 140 90 1 200 1.6 19 0.5 4.9 30 36 93 2 2
69 21 G3A2 37 160 100 2 150 1.4 20 0.6 6.5 30 34 96 1 1 LSCS 160 90 1 150 1.4 20 0.6 6 30 34 95 2 1 140 90 trace 150 1.5 20 0.5 5 30 32 92 2 2
70 24 G2P1L1 37 epigastric pain, headache 150 110 2 100 1.8 18 0.5 5.9 35 39 71 1 1 + NVD 140 100 1 100 1.9 18 0.5 5 34 36 69 2 1 + 130 90 trace 150 1.9 18 0.5 4.5 34 36 94 2 2
71 18 Primi 36 epigastric pain ,decreased urine output 160 120 3 30 1 36 0.9 8.9 101 107 206 2 1 + LSCS 150 100 2 150 1.5 30 0.7 7.2 88 86 154 2 1 + 140 90 1 100 1.6 26 0.7 6.1 46 40 96 2 2
72 27 G2P1L0 38 170 100 2 100 1.2 22 0.4 5.8 28 25 78 2 1 + LSCS 150 90 1 100 1.2 21 0.4 5 28 25 76 2 1 + 140 90 1 100 1.4 21 0.3 4.8 28 25 76 2 2
73 25 G2P1L2 37 160 100 2 100 1.3 24 0.7 5.7 37 39 76 2 1 NVD 150 90 1 150 1.4 23 0.6 4.9 35 37 75 2 1 140 90 trace 150 1.4 22 0.6 4.3 35 37 75 2 2
74 28 Primi 36 160 110 1 50 1.5 17 0.6 6.8 95 98 164 2 1 + LSCS 150 100 trace 100 1.5 17 0.5 6.5 72 78 111 2 1 + 140 90 trace 100 1.5 16 0.5 5.9 50 49 93 2 2
75 31 Primi 35 150 110 2 100 1.9 16 0.3 6.5 24 25 66 2 1 NVD 150 100 1 100 1.9 15 0.3 6 24 24 65 2 1 140 90 trace 150 1.4 15 0.2 5.3 24 24 65 2 2
76 32 G4P3L3 37 160 100 2 100 1.8 16 0.4 6.4 37 39 72 2 1 NVD 140 100 1 150 1.8 16 0.4 5.9 35 37 72 2 1 130 90 trace 150 2 15 0.4 4 35 37 72 2 2
77 21 Primi 38 headache ,decreased urine output 170 100 2 40 1 35 0.8 8.7 39 40 86 2 1 + LSCS 160 90 1 100 1.3 30 0.7 7.9 38 40 80 2 1 + 140 90 1 100 1.5 26 0.7 6.1 35 39 80 2 2
78 23 G2P1L0 34 headache ,decreased urine output 160 110 2 50 1 33 0.8 8.5 61 59 164 2 1 + LSCS 150 90 1 100 1.2 29 0.6 7.8 56 56 103 2 1 + 140 90 1 100 1.4 25 0.6 6 42 40 80 2 2
79 30 Primi 38 160 100 1 100 1.7 20 0.7 6.6 31 33 74 2 1 NVD 160 90 trace 150 1.7 20 0.6 6.6 31 32 72 2 1 140 90 trace 150 1.7 20 0.5 5.3 31 30 70 2 2
80 28 G3P1L1A1 37 160 110 1 100 1.6 21 0.7 6.5 22 26 66 2 1 NVD 150 100 trace 100 1.6 21 0.6 5.5 22 26 66 2 1 140 90 trace 150 1.6 19 0.6 4.8 22 25 64 2 2
81 31 G3P1L1A1 36 160 110 1 100 1 24 0.8 7.8 32 36 97 2 2 NVD 150 100 1 100 1.5 24 0.8 6.2 32 36 96 2 2 140 90 trace 150 1.5 23 0.7 5.9 32 36 95 2 2
82 29 G2A1 36 160 110 2 50 1.2 22 0.7 7.2 34 30 95 2 2 LSCS 150 90 1 100 1.2 21 0.7 6 32 30 95 2 1 140 90 1 100 1.3 20 0.7 4.8 32 30 95 2 2
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83 27 Primi 37 150 100 2 100 1.4 26 0.6 6.3 28 25 87 2 2 LSCS 140 90 1 150 1.5 26 0.6 4.2 28 25 86 2 130 90 trace 150 1.5 25 0.6 4 28 25 86 2 1
84 22 Primi 30 decreased urine output, 170 120 3 30 1 30 0.9 9.2 72 78 186 2 2 + NVD 150 100 2 50 1.4 28 0.8 5.8 69 63 150 2 2 + 140 90 1 100 1.7 23 0.7 4.1 42 40 97 2 1 2
85 24 G2A1 36 headache, epigastric pain 160 120 2 50 1.2 23 0.8 6.8 99 99 192 1 1 + NVD 160 90 trace 100 2 23 0.8 5 83 78 137 2 1 + 130 90 trace 150 2.1 22 0.6 4 45 48 94 2 2
86 30 G2P1L0 37 150 110 2 100 1.8 18 0.5 6 43 35 75 1 1 LSCS 140 100 1 100 1.8 18 0.5 4.9 43 35 74 2 1 130 90 trace 100 1.8 16 0.4 4.7 42 35 74 2 2
87 32 G3P2L2 37 150 100 3 150 1.5 18 0.5 5.9 34 38 66 2 2 NVD 140 90 2 150 1.5 18 0.5 5.8 33 37 90 2 130 80 1 200 1.6 18 0.4 4.9 33 37 90 1 2
88 29 Primi 37 170 110 2 100 1.6 26 0.6 6.8 39 37 91 2 2 + LSCS 150 100 1 150 1.6 25 0.6 6.6 39 37 90 2 2 + 140 90 trace 150 1.7 26 0.6 5 39 37 90 2 2
89 27 Primi 38 160 100 1 100 1.5 18 0.5 7.2 31 35 91 2 2 LSCS 150 100 1 100 1.5 18 0.5 7.1 30 35 91 2 2 150 90 1 150 1.5 16 0.5 6.1 30 35 91 2 1 2
90 29 G2A1 37 150 110 2 100 1.8 20 0.5 7.9 32 34 82 2 2 NVD 140 100 1 100 1.8 20 0.5 6.8 32 34 80 2 1 140 90 1 100 2 18 0.5 5.9 32 34 80 2 2
91 30 Primi 37 150 100 2 50 1.4 22 0.4 7 49 45 98 2 2 NVD 140 90 2 100 1.6 22 0.3 6 44 43 95 2 130 90 1 150 1.6 21 0.4 5.1 42 42 94 2 1
92 31 Primi 38 150 100 2 50 1.5 24 0.6 6.8 36 38 87 2 2 NVD 140 100 2 100 1.5 24 0.5 5.9 34 36 87 2 1 140 90 1 100 1.5 24 0.5 5.7 34 35 86 2 2
93 30 G3P1L1D1 38 160 100 2 100 1.7 26 0.5 6.4 34 39 89 2 2 NVD 140 90 1 150 1.6 25 0.5 6 34 36 88 2 130 90 trace 150 1.7 25 0.5 5.4 32 34 87 2 2
94 29 G3P2L2 38 160 100 2 100 1.9 28 0.7 6.2 22 28 89 2 2 LSCS 150 100 1 100 1.9 28 0.7 5.8 22 27 87 2 2 140 90 trace 100 2 28 0.7 5 22 27 87 2 1 2
95 26 Primi 37 160 100 2 100 1.6 20 0.6 6.6 35 30 88 2 2 NVD 150 100 2 100 1.6 20 0.6 6 35 29 87 2 2 130 90 1 150 1.6 18 0.5 5.1 35 28 86 2 1 2
96 27 Primi 40 150 100 2 100 1.5 18 0.5 6.1 34 31 96 2 2 LSCS 140 100 1 150 1.5 18 0.5 5.4 34 31 90 2 1 130 90 1 150 1.6 17 0.5 5 34 31 90 2 2
97 25 G3A2 32 decreased urine output, headahe 150 110 3 30 1 32 0.9 8.8 72 69 158 1 1 + NVD 140 100 2 100 1.3 26 0.8 6.6 43 40 98 2 1 + 130 90 1 150 1.5 25 0.6 5.3 40 39 96 2 2
98 25 G2A1 36 160 110 1 100 1.5 28 0.5 7 36 31 85 1 1 NVD 150 90 1 100 1.5 24 0.5 6.2 35 31 80 2 1 140 90 trace 150 1.6 22 0.4 5.9 34 30 80 2 2
99 23 Primi 37 150 100 2 50 1.4 26 0.4 6.8 38 32 97 1 1 NVD 140 100 1 100 1.3 24 0.3 6.1 35 32 95 2 1 140 90 trace 100 1.5 20 0.3 5.8 35 32 94 2 2
100 28 G3P1L1 37 160 100 1 100 1.3 25 0.6 6.1 39 35 87 2 2 LSCS 150 90 trace 150 1.4 25 0.6 5.7 37 35 86 2 1 140 80 trace 150 1.4 25 0.5 5.7 37 34 84 2 2
DAY   2DAY    1CASES - CURETTAGE DONE PATIENTS
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stay in
hospital
1 30 G2P1L1 37 160 110 2 100 1.5 22 0.6 6.3 34 36 76 2 2 LSCS 160 100 2 100 1.5 22 0.6 6.3 34 36 76 2 2 150 100 1 100 1.6 21 0.6 6 34 36 76 2 2 3
2 25 G2P1L0 38 160 110 1 100 1.6 25 0.7 6.5 42 40 97 2 2 NVD 150 110 1 100 1.5 25 0.7 6.3 40 40 96 2 2 150 100 trace 100 1.7 25 0.6 6 40 39 95 2 2 3
3 18 Primi 34 headache ,decreased urine output 170 120 2 30 1 38 0.9 8.5 75 79 154 2 2 + NVD 160 110 2 50 1.1 38 0.8 8 62 69 111 2 2 + 160 100 1 50 1.1 37 0.8 7.9 62 68 110 2 2 + 3
4 20 Primi 37 160 110 2 100 1.5 26 0.7 6.4 38 36 87 2 2 LSCS 150 100 1 100 1.5 25 0.7 6.3 38 36 87 2 2 150 90 1 100 1.5 25 0.7 6.2 38 36 86 2 1 2
5 31 G3P1L1A1 37 150 110 1 100 1.7 21 0.7 5.9 32 34 79 2 2 LSCS 150 110 1 50 1.7 21 0.7 5.8 32 34 79 2 2 140 100 trace 50 1.8 21 0.7 5.8 31 33 78 2 2 2
6 21 Primi 34 150 100 1 50 1.3 29 0.6 7.2 25 27 66 2 2 NVD 160 100 1 100 1.3 29 0.6 7 24 25 66 2 2 150 100 1 100 1.3 27 0.6 7 23 25 65 2 2 3
7 22 Primi 36 160 110 2 50 1.8 26 0.5 7 42 39 87 2 2 LSCS 150 100 2 50 1.8 26 0.5 7 42 38 87 2 2 150 100 2 100 1.8 26 0.4 6.9 41 38 86 2 2 3
8 19 Primi 34 headache 160 110 2 50 1.3 18 0.5 7.1 36 38 85 2 2 + NVD 160 100 1 100 1.3 18 0.5 7 36 38 85 2 2 + 150 100 1 100 1.4 18 0.5 7 36 38 85 2 2 + 3
9 28 G2A1 37 160 90 1 100 1.9 16 0.3 6.9 37 35 79 2 2 LSCS 150 90 1 100 1.9 16 0.3 6.8 37 35 79 2 1 140 90 1 100 1.9 16 0.3 6.5 37 35 79 2 2
10 20 Primi 37 150 110 1 100 1.6 20 0.4 6.8 30 32 88 2 2 LSCS 140 100 1 100 1.6 20 0.4 6.5 30 32 87 2 2 140 100 trace 100 1.7 20 0.4 6.5 30 32 87 2 2 2
11 18 Primi 38 160 100 1 100 1.5 21 0.6 6.7 31 32 91 2 2 NVD 150 100 1 150 1.5 21 0.6 6.6 31 32 90 2 2 150 100 1 100 1.5 20 0.6 6.6 31 32 91 2 2 3
12 24 Primi 39 160 110 2 100 1.3 22 0.6 6 39 40 96 2 2 NVD 160 100 2 150 1.3 22 0.6 6 39 40 96 2 2 150 100 1 150 1.4 21 0.5 5.9 38 40 95 2 2 3
13 22 Primi 40 160 100 1 150 1.2 19 0.5 6.7 41 40 98 2 2 LSCS 160 90 1 100 1.4 19 0.5 6.7 40 40 98 2 1 150 90 trace 100 1.4 19 0.5 6.6 40 39 95 2 1 2
14 20 G2A1 30 headache ,decreased urine output 160 110 2 100 1 37 0.8 9 72 78 169 1 1 + LSCS 160 100 2 50 1 35 0.7 8.5 69 67 119 2 2 + 160 100 2 50 1 35 0.7 8 65 66 110 2 2 + 3
15 21 Primi 38 150 110 2 30 1.4 25 0.7 7.2 41 38 94 2 2 LSCS 150 100 1 100 1.4 25 0.7 7.1 40 38 93 2 2 150 90 1 100 1.4 23 0.6 6.9 40 38 92 2 1 2
16 29 G2P1L1 37 160 100 2 100 1.6 24 0.6 5.9 32 30 88 2 2 NVD 150 90 1 100 1.5 24 0.6 5.7 32 30 88 2 1 140 90 1 100 1.5 24 0.6 5.5 32 30 88 2 2
17 20 G2A1 37 150 100 2 100 1.7 25 0.7 6 35 35 97 2 2 NVD 140 100 2 100 1.7 24 0.7 6 35 35 97 2 2 140 90 1 100 1.8 23 0.7 5.7 35 35 97 2 2
18 19 Primi 34 headache , blurring of vision 160 120 2 100 1 39 0.8 8.9 75 79 151 2 2 + NVD 160 110 2 50 1 37 0.8 8.5 74 73 132 2 2 + 150 100 1 50 1.1 37 0.8 8.4 73 71 112 2 2 + 3
DAY   2DAY    1CONTROLS - CURETTAGE NOT DONE DAY    2
19 26 G2P1L1 37 160 100 2 50 1.8 24 0.3 6.8 34 32 85 1 1 LSCS 150 100 1 50 1.8 24 0.3 6.5 34 32 85 2 2 150 90 1 100 1.9 22 0.3 6.5 32 32 84 2 1 2
20 23 Primi 37 160 100 1 50 1.6 23 0.5 5.9 38 36 80 2 2 LSCS 150 90 trace 100 1.6 23 0.5 5.7 38 35 84 2 1 150 90 trace 100 1.7 23 0.5 5.7 38 34 84 2 1 2
21 28 Primi 37 170 120 1 100 1.5 15 0.6 5.8 37 37 98 2 2 + NVD 160 100 1 150 1.5 15 0.5 5.8 37 36 97 2 2 + 150 100 1 150 1.6 15 0.5 5.5 37 36 96 2 2 + 3
22 23 Primi 37 150 100 2 150 1.4 16 0.7 6.1 30 39 91 1 1 LSCS 140 100 1 100 1.5 16 0.7 6 30 35 91 2 2 140 90 1 100 1.5 15 0.7 6 30 34 90 2 2
23 22 Primi 40 160 110 2 100 1.3 20 0.3 5.7 32 31 95 2 2 LSCS 150 100 2 100 1.4 20 0.3 5.5 32 31 95 2 2 150 90 2 100 1.4 20 0.3 5.5 32 31 95 2 1 2
24 21 Primi 38 decreased urine output 170 110 3 50 1.1 33 0.9 8.8 85 89 175 2 2 + NVD 160 100 2 50 1.2 33 0.8 8 85 85 154 2 2 + 160 100 2 50 1.1 32 0.8 8 85 82 118 2 2 + 3
25 27 G3P1L1D1 39 150 110 1 30 1.6 22 0.5 6.9 38 35 96 2 2 NVD 140 100 trace 150 1.5 22 0.5 6.5 38 35 96 2 2 140 90 trace 150 1.6 21 0.5 6.3 38 34 95 2 2
26 19 G2A1 38 160 100 1 150 1.5 21 0.6 6.6 38 37 92 2 2 LSCS 150 100 1 100 1.8 21 0.6 6.6 38 37 92 2 2 140 100 1 100 1.8 21 0.5 6.5 37 36 92 2 2 2
27 25 G2P1LO 37 160 100 2 100 1.7 22 0.6 6.5 39 38 79 2 2 NVD 150 90 1 100 1.7 22 0.5 6.5 39 37 78 2 1 150 90 trace 100 1.8 22 0.5 6.5 39 37 78 2 1 2
28 20 Primi 37 headache , blurring of vision 160 120 2 50 1.1 29 0.8 8.1 79 76 121 2 2 + NVD 160 110 2 50 1.1 29 0.8 8 78 76 119 2 2 + 150 110 2 50 1.2 27 0.7 7.5 78 75 117 2 2 + 4
29 22 Primi 36 150 100 1 150 1.5 24 0.7 7.2 32 30 68 2 2 NVD 150 90 1 150 1.5 24 0.7 7 32 30 68 2 1 140 90 1 150 1.6 24 0.7 7 32 30 65 2 2
30 23 Primi 37 150 110 1 100 1.4 26 0.5 7.3 41 40 93 2 2 LSCS 150 100 1 100 1.4 26 0.5 7.3 41 40 92 2 2 140 100 trace 150 1.4 25 0.5 7.2 41 40 91 2 2 2
31 29 G2P1L1 36 160 100 2 100 1.3 25 0.6 6.8 39 30 75 2 2 LSCS 150 90 1 100 1.3 25 0.6 6.5 39 30 75 2 1 150 90 1 100 1.4 25 0.6 6.5 39 30 74 2 1 2
32 31 G2P1L1 37 160 110 1 50 1.2 24 0.6 6.7 37 36 99 2 2 LSCS 150 100 1 50 1.2 24 0.6 6.5 37 36 99 2 2 150 90 1 50 1.3 24 0.6 6.4 37 36 97 2 1 3
33 22 G2A1 37 150 110 1 100 1.6 17 0.5 6 45 40 97 2 2 LSCS 140 100 trace 100 1.6 17 0.5 6 45 40 97 2 2 140 100 trace 100 1.6 17 0.5 6 45 40 96 2 2 3
34 26 Primi 34 headache 170 110 1 50 1.5 18 0.4 6 30 30 88 2 2 + NVD 160 100 1 50 1.5 18 0.4 5.8 29 29 88 2 2 + 150 90 1 150 1.5 18 0.4 5.8 29 28 90 2 1 + 2
35 25 Primi 36 160 100 2 100 1.1 16 0.3 6.1 31 33 73 2 2 LSCS 150 100 1 100 1.1 16 0.3 6 31 33 73 2 2 150 90 trace 100 1.1 16 0.3 6 31 32 73 2 1 2
36 20 Primi 37 160 110 2 100 1.3 20 0.7 6.3 34 32 82 2 2 LSCS 160 100 2 100 1.3 20 0.6 6 34 32 81 2 2 150 90 1 100 1.3 20 0.8 5.9 34 31 80 2 1 2
37 32 Primi 37 160 110 1 100 1.5 22 0.6 6.3 36 38 89 2 2 NVD 160 100 2 100 1.5 22 0.6 6.3 35 37 90 2 2 150 100 1 100 1.6 21 0.6 6 35 37 90 2 2 4
38 21 Primi 36 150 100 2 100 1.6 25 0.7 6.5 38 38 90 2 2 NVD 150 110 1 100 1.5 25 0.7 6.3 38 38 90 2 2 150 100 trace 100 1.7 25 0.6 6 38 38 90 2 2 4
39 18 Primi 34 decreased urine output 170 120 2 30 1 38 0.9 8.5 79 81 152 2 2 + NVD 160 110 2 50 1.1 38 0.8 8 78 79 143 2 2 + 160 100 1 50 1.1 37 0.8 7.9 77 77 126 2 2 + 4
40 27 G2P1L2 37 160 110 1 100 1.5 26 0.7 6.4 48 46 85 2 2 LSCS 160 100 1 100 1.5 25 0.7 6.3 43 46 85 2 2 150 90 1 100 1.5 25 0.7 6.2 43 46 85 2 1 2
41 24 Primi 37 150 100 1 50 1.7 21 0.7 5.9 41 39 89 2 2 NVD 150 110 1 50 1.7 21 0.7 5.8 40 39 87 2 2 140 100 trace 50 1.8 21 0.7 5.8 40 39 86 2 2 3
42 23 G2A1 38 170 100 2 50 1.3 19 0.6 7.2 38 33 79 2 2 NVD 160 100 1 100 1.3 29 0.6 7 38 33 78 2 2 150 100 1 100 1.3 27 0.6 7 38 33 78 2 2 3
43 25 G2P1L1 38 160 100 2 50 1.8 26 0.5 7 34 36 86 2 2 NVD 150 100 2 50 1.8 26 0.5 7 34 36 86 2 2 150 100 2 100 1.8 26 0.4 6.9 34 35 85 2 2 3
44 22 Primi 39 170 110 1 100 1.3 18 0.5 7.1 36 38 91 2 2 NVD 160 100 1 100 1.3 18 0.5 7 36 38 90 2 2 150 100 1 100 1.4 18 0.5 7 36 37 90 2 2 3
45 26 Primi 38 160 90 1 100 1.9 16 0.3 6.9 37 35 90 2 2 LSCS 150 90 1 100 1.9 16 0.3 6.8 37 35 90 2 1 140 90 1 100 1.9 16 0.3 6.5 37 34 89 2 2
46 24 G2A1 37 150 110 1 100 1.6 20 0.4 6.8 30 32 88 2 2 LSCS 140 100 1 100 1.6 20 0.4 6.5 30 32 88 2 2 140 100 trace 100 1.7 20 0.4 6.5 30 32 88 2 2 3
47 23 Primi 37 160 100 2 100 1.5 21 0.6 6.7 31 32 90 2 2 LSCS 150 100 1 100 1.5 21 0.6 6.6 31 32 90 2 2 150 100 1 100 1.5 20 0.6 6.6 31 31 89 2 2 3
48 21 Primi 36 160 110 2 150 1.3 22 0.6 6 39 35 93 2 2 NVD 160 100 2 150 1.3 22 0.6 6 39 35 92 2 2 150 100 1 150 1.4 21 0.5 5.9 39 35 91 2 2 3
49 22 G3A2 34 headache ,decreased urine output 160 110 2 30 1 37 0.8 8.9 87 89 153 2 2 + NVD 160 100 2 50 1 35 0.7 8.5 85 84 123 2 2 + 160 100 2 50 1 35 0.7 8 84 84 112 2 2 + 4
50 24 Primi 37 150 110 2 100 1.4 25 0.7 7.2 36 37 89 2 2 LSCS 150 100 1 100 1.4 25 0.7 7.1 35 36 88 2 2 150 90 1 100 1.4 23 0.6 6.9 35 34 88 2 1 2
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DAY   2DAY    1CONTROLS - CURETTAGE NOT DONE DAY    2
51 28 G3P2L2 30 headache ,decreased urine output 160 110 2 100 1 37 0.8 9 72 78 169 1 1 + NVD 160 100 2 50 1 35 0.7 8.5 69 67 119 2 2 + 160 100 2 50 1 35 0.7 8 65 66 110 2 2 + 3
52 32 G2P1L1 38 150 110 2 30 1.4 25 0.7 7.2 41 38 94 2 2 LSCS 150 100 1 100 1.4 25 0.7 7.1 40 38 93 2 2 150 90 1 100 1.4 23 0.6 6.9 40 38 92 2 1 2
53 27 G2P1L1 37 160 100 2 100 1.6 24 0.6 5.9 32 30 88 2 2 NVD 150 90 1 100 1.5 24 0.6 5.7 32 30 88 2 1 140 90 1 100 1.5 24 0.6 5.5 32 30 88 2 2
54 24 Primi 37 150 100 2 100 1.7 25 0.7 6 35 35 97 2 2 NVD 140 100 2 100 1.7 24 0.7 6 35 35 97 2 2 140 90 1 100 1.8 23 0.7 5.7 35 35 97 2 2
55 24 G2A1 34 headache , blurring of vision 160 120 2 100 1 39 0.8 8.9 75 79 151 2 2 + NVD 160 110 2 50 1 37 0.8 8.5 74 73 132 2 2 + 150 100 1 50 1.1 37 0.8 8.4 73 71 112 2 2 + 3
56 27 G2P1L0 37 160 100 2 50 1.8 24 0.3 6.8 34 32 85 1 1 LSCS 150 100 1 50 1.8 24 0.3 6.5 34 32 85 2 2 150 90 1 100 1.9 22 0.3 6.5 32 32 84 2 1 2
57 19 Primi 37 160 100 1 50 1.6 23 0.5 5.9 38 36 80 2 2 LSCS 150 90 trace 100 1.6 23 0.5 5.7 38 35 84 2 1 150 90 trace 100 1.7 23 0.5 5.7 38 34 84 2 1 2
58 27 Primi 37 170 120 1 100 1.5 15 0.6 5.8 37 37 98 2 2 + NVD 160 100 1 150 1.5 15 0.5 5.8 37 36 97 2 2 + 150 100 1 150 1.6 15 0.5 5.5 37 36 96 2 2 + 3
59 22 Primi 37 150 100 2 150 1.4 16 0.7 6.1 30 39 91 1 1 LSCS 140 100 1 100 1.5 16 0.7 6 30 35 91 2 2 140 90 1 100 1.5 15 0.7 6 30 34 90 2 2
60 29 G2P1L0 40 160 110 2 100 1.3 20 0.3 5.7 32 31 95 2 2 LSCS 150 100 2 100 1.4 20 0.3 5.5 32 31 95 2 2 150 90 2 100 1.4 20 0.3 5.5 32 31 95 2 1 2
61 19 Primi 38 decreased urine output 170 110 3 50 1.1 33 0.9 8.8 85 89 175 2 2 + LSCS 160 100 2 50 1.2 33 0.8 8 85 85 154 2 2 + 160 100 2 50 1.1 32 0.8 8 85 82 118 2 2 + 3
62 20 G2A1 39 150 110 1 30 1.6 22 0.5 6.9 38 35 96 2 2 LSCS 140 100 trace 150 1.5 22 0.5 6.5 38 35 96 2 2 140 90 trace 150 1.6 21 0.5 6.3 38 34 95 2 2
63 31 Primi 38 160 100 1 150 1.5 21 0.6 6.6 38 37 92 2 2 LSCS 150 100 1 100 1.8 21 0.6 6.6 38 37 92 2 2 140 100 1 100 1.8 21 0.5 6.5 37 36 92 2 2 2
64 30 G2P1L1 37 160 100 2 100 1.7 22 0.6 6.5 39 38 79 2 2 NVD 150 90 1 100 1.7 22 0.5 6.5 39 37 78 2 1 150 90 trace 100 1.8 22 0.5 6.5 39 37 78 2 1 2
65 21 Primi 37 headache , blurring of vision 160 120 2 50 1.1 29 0.8 8.1 79 76 121 2 2 + LSCS 160 110 2 50 1.1 29 0.8 8 78 76 119 2 2 + 150 110 2 50 1.2 27 0.7 7.5 78 75 117 2 2 + 4
66 23 Primi 36 150 100 1 150 1.5 24 0.7 7.2 32 30 68 2 2 LSCS 150 90 1 150 1.5 24 0.7 7 32 30 68 2 1 140 90 1 150 1.6 24 0.7 7 32 30 65 2 2
67 28 Primi 37 150 110 1 100 1.4 26 0.5 7.3 41 40 93 2 2 LSCS 150 100 1 100 1.4 26 0.5 7.3 41 40 92 2 2 140 100 trace 150 1.4 25 0.5 7.2 41 40 91 2 2 2
68 24 Primi 36 160 100 2 100 1.3 25 0.6 6.8 39 30 75 2 2 LSCS 150 90 1 100 1.3 25 0.6 6.5 39 30 75 2 1 150 90 1 100 1.4 25 0.6 6.5 39 30 74 2 1 2
69 21 Primi 37 160 110 1 50 1.2 24 0.6 6.7 37 36 99 2 2 LSCS 150 100 1 50 1.2 24 0.6 6.5 37 36 99 2 2 150 90 1 50 1.3 24 0.6 6.4 37 36 97 2 1 3
70 29 G2P1L1 37 150 110 1 100 1.6 17 0.5 6 45 40 97 2 2 LSCS 140 100 trace 100 1.6 17 0.5 6 45 40 97 2 2 140 100 trace 100 1.6 17 0.5 6 45 40 96 2 2 3
71 24 G2P1L1 34 headache 170 110 1 50 1.5 18 0.4 6 30 30 88 2 2 + NVD 160 100 1 50 1.5 18 0.4 5.8 29 29 88 2 2 + 150 90 1 150 1.5 18 0.4 5.8 29 28 90 2 1 + 2
72 25 Primi 36 160 100 2 100 1.1 16 0.3 6.1 31 33 73 2 2 LSCS 150 100 1 100 1.1 16 0.3 6 31 33 73 2 2 150 90 trace 100 1.1 16 0.3 6 31 32 73 2 1 2
73 30 Primi 37 160 110 2 100 1.3 20 0.7 6.3 34 32 82 2 2 LSCS 160 100 2 100 1.3 20 0.6 6 34 32 81 2 2 150 90 1 100 1.3 20 0.8 5.9 34 31 80 2 1 2
74 19 Primi 37 160 110 1 100 1.5 22 0.6 6.3 36 38 89 2 2 LSCS 160 100 2 100 1.5 22 0.6 6.3 35 37 90 2 2 150 100 1 100 1.6 21 0.6 6 35 37 90 2 2 4
75 26 G3A2 36 150 100 2 100 1.6 25 0.7 6.5 38 38 90 2 2 NVD 150 110 1 100 1.5 25 0.7 6.3 38 38 90 2 2 150 100 trace 100 1.7 25 0.6 6 38 38 90 2 2 4
76 28 G2A1 34 decreased urine output 170 120 2 30 1 38 0.9 8.5 79 81 152 2 2 + NVD 160 110 2 50 1.1 38 0.8 8 78 79 143 2 2 + 160 100 1 50 1.1 37 0.8 7.9 77 77 126 2 2 + 4
77 22 Primi 37 160 110 1 100 1.5 26 0.7 6.4 48 46 85 2 2 LSCS 160 100 1 100 1.5 25 0.7 6.3 43 46 85 2 2 150 90 1 100 1.5 25 0.7 6.2 43 46 85 2 1 2
78 31 Primi 37 150 100 1 50 1.7 21 0.7 5.9 41 39 89 2 2 LSCS 150 110 1 50 1.7 21 0.7 5.8 40 39 87 2 2 140 100 trace 50 1.8 21 0.7 5.8 40 39 86 2 2 3
79 20 Primi 38 170 100 2 50 1.3 19 0.6 7.2 38 33 79 2 2 NVD 160 100 1 100 1.3 29 0.6 7 38 33 78 2 2 150 100 1 100 1.3 27 0.6 7 38 33 78 2 2 3
80 26 G2P1L1 38 160 100 2 50 1.8 26 0.5 7 34 36 86 2 2 LSCS 150 100 2 50 1.8 26 0.5 7 34 36 86 2 2 150 100 2 100 1.8 26 0.4 6.9 34 35 85 2 2 3
81 25 Primi 34 headache ,decreased urine output 170 120 2 30 1 38 0.9 8.5 75 79 154 2 2 + NVD 160 110 2 50 1.1 38 0.8 8 62 69 111 2 2 + 160 100 1 50 1.1 37 0.8 7.9 62 68 110 2 2 + 3
82 22 G2A1 37 160 110 2 100 1.5 26 0.7 6.4 38 36 87 2 2 LSCS 160 100 1 100 1.5 25 0.7 6.3 38 36 87 2 2 150 90 1 100 1.5 25 0.7 6.2 38 36 86 2 1 2
83 27 G2P1L1 37 150 110 1 100 1.7 21 0.7 5.9 32 34 79 2 2 LSCS 150 110 1 50 1.7 21 0.7 5.8 32 34 79 2 2 140 100 trace 50 1.8 21 0.7 5.8 31 33 78 2 2 2
84 21 Primi 34 150 100 1 50 1.3 29 0.6 7.2 25 27 66 2 2 NVD 160 100 1 100 1.3 29 0.6 7 24 25 66 2 2 150 100 1 100 1.3 27 0.6 7 23 25 65 2 2 3
85 29 G4P1L1D2 36 160 110 2 50 1.8 26 0.5 7 42 39 87 2 2 LSCS 150 100 2 50 1.8 26 0.5 7 42 38 87 2 2 150 100 2 100 1.8 26 0.4 6.9 41 38 86 2 2 3
86 24 G3A2 38 headache 160 110 2 50 1.3 18 0.5 7.1 36 38 85 2 2 + LSCS 160 100 1 100 1.3 18 0.5 7 36 38 85 2 2 + 150 100 1 100 1.4 18 0.5 7 36 38 85 2 2 + 3
87 27 Primi 37 160 90 1 100 1.9 16 0.3 6.9 37 35 79 2 2 LSCS 150 90 1 100 1.9 16 0.3 6.8 37 35 79 2 1 140 90 1 100 1.9 16 0.3 6.5 37 35 79 2 2
88 25 Primi 37 150 110 1 100 1.6 20 0.4 6.8 30 32 88 2 2 LSCS 140 100 1 100 1.6 20 0.4 6.5 30 32 87 2 2 140 100 trace 100 1.7 20 0.4 6.5 30 32 87 2 2 2
89 22 Primi 38 160 100 1 100 1.5 21 0.6 6.7 31 32 91 2 2 NVD 150 100 1 150 1.5 21 0.6 6.6 31 32 90 2 2 150 100 1 100 1.5 20 0.6 6.6 31 32 91 2 2 3
90 23 Primi 39 160 110 2 100 1.3 22 0.6 6 39 40 96 2 2 NVD 160 100 2 150 1.3 22 0.6 6 39 40 96 2 2 150 100 1 150 1.4 21 0.5 5.9 38 40 95 2 2 3
91 30 G2P1L1 40 160 100 1 150 1.2 19 0.5 6.7 41 40 98 2 2 LSCS 160 90 1 100 1.4 19 0.5 6.7 40 40 98 2 1 150 90 trace 100 1.4 19 0.5 6.6 40 39 95 2 1 2
92 29 G2P1L0 30 headache ,decreased urine output 160 110 2 100 1 37 0.8 9 72 78 169 1 1 + LSCS 160 100 2 50 1 35 0.7 8.5 69 67 119 2 2 + 160 100 2 50 1 35 0.7 8 65 66 110 2 2 + 3
93 19 Primi 38 150 110 2 30 1.4 25 0.7 7.2 41 38 94 2 2 LSCS 150 100 1 100 1.4 25 0.7 7.1 40 38 93 2 2 150 90 1 100 1.4 23 0.6 6.9 40 38 92 2 1 2
94 25 Primi 37 160 100 2 100 1.6 24 0.6 5.9 32 30 88 2 2 LSCS 150 90 1 100 1.5 24 0.6 5.7 32 30 88 2 1 140 90 1 100 1.5 24 0.6 5.5 32 30 88 2 2
95 22 G2P1L1 37 150 100 2 100 1.7 25 0.7 6 35 35 97 2 2 LSCS 140 100 2 100 1.7 24 0.7 6 35 35 97 2 2 140 90 1 100 1.8 23 0.7 5.7 35 35 97 2 2
96 24 G2P1L1 34 headache , blurring of vision 160 120 2 100 1 39 0.8 8.9 75 79 151 2 2 + NVD 160 110 2 50 1 37 0.8 8.5 74 73 132 2 2 + 150 100 1 50 1.1 37 0.8 8.4 73 71 112 2 2 + 3
97 26 G3P1L1A1 37 160 100 2 50 1.8 24 0.3 6.8 34 32 85 1 1 LSCS 150 100 1 50 1.8 24 0.3 6.5 34 32 85 2 2 150 90 1 100 1.9 22 0.3 6.5 32 32 84 2 1 2
98 22 Primi 37 160 100 1 50 1.6 23 0.5 5.9 38 36 80 2 2 LSCS 150 90 trace 100 1.6 23 0.5 5.7 38 35 84 2 1 150 90 trace 100 1.7 23 0.5 5.7 38 34 84 2 1 2
99 21 Primi 37 170 120 1 100 1.5 15 0.6 5.8 37 37 98 2 2 + LSCS 160 100 1 150 1.5 15 0.5 5.8 37 36 97 2 2 + 150 100 1 150 1.6 15 0.5 5.5 37 36 96 2 2 + 3
100 28 G2P1L0 37 150 100 2 150 1.4 16 0.7 6.1 30 39 91 1 1 LSCS 140 100 1 100 1.5 16 0.7 6 30 35 91 2 2 140 90 1 100 1.5 15 0.7 6 30 34 90 2 2

